WO2014187957A1 - Tylosin derivatives and method for preparation thereof - Google Patents

Tylosin derivatives and method for preparation thereof Download PDF

Info

Publication number
WO2014187957A1
WO2014187957A1 PCT/EP2014/060665 EP2014060665W WO2014187957A1 WO 2014187957 A1 WO2014187957 A1 WO 2014187957A1 EP 2014060665 W EP2014060665 W EP 2014060665W WO 2014187957 A1 WO2014187957 A1 WO 2014187957A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
spp
aryl
substituted
compound
Prior art date
Application number
PCT/EP2014/060665
Other languages
French (fr)
Inventor
Gerd Kleefeld
Robrecht Froyman
Carolin LUDWIG
Satoshi Omura
Toshiaki Sunazuka
Hirose TOMOYASU
Sugawara AKIHIRO
Shiomi KAZURO
Original Assignee
Bayer Animal Health Gmbh
Kitasato Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48463869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014187957(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BR112015029260A priority Critical patent/BR112015029260A2/en
Priority to NZ714071A priority patent/NZ714071B2/en
Priority to CA2913098A priority patent/CA2913098C/en
Priority to PL14725726T priority patent/PL2999707T3/en
Priority to KR1020157035927A priority patent/KR102307218B1/en
Priority to CN201480041371.2A priority patent/CN105408340B/en
Priority to RU2015155032A priority patent/RU2714482C2/en
Priority to US14/891,762 priority patent/US9771389B2/en
Priority to JP2016514434A priority patent/JP6494600B2/en
Priority to UAA201512523A priority patent/UA117751C2/en
Priority to AU2014270353A priority patent/AU2014270353B2/en
Priority to DK14725726.5T priority patent/DK2999707T3/en
Priority to MYPI2015704210A priority patent/MY184630A/en
Priority to NO14725726A priority patent/NO2999707T3/no
Priority to ES14725726.5T priority patent/ES2669615T3/en
Priority to EP14725726.5A priority patent/EP2999707B1/en
Priority to SI201430717T priority patent/SI2999707T1/en
Priority to MX2015016118A priority patent/MX361808B/en
Application filed by Bayer Animal Health Gmbh, Kitasato Institute filed Critical Bayer Animal Health Gmbh
Publication of WO2014187957A1 publication Critical patent/WO2014187957A1/en
Priority to IL242543A priority patent/IL242543B/en
Priority to HK16104565.9A priority patent/HK1216753A1/en
Priority to HRP20180877TT priority patent/HRP20180877T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Definitions

  • the present invention relates to new macrolide derivatives, in particular new tylosin derivatives; a pharmaceutical or veterinary composition comprising any of the derivatives; a method for preparation thereof; a method for treating and/or preventing bacterial infections in an animal, wherein the method comprises administering any of the derivatives or the composition; and a use of the derivatives for the manufacture of medicaments for treating and/or preventing bacterial infections in an animal.
  • Macrolides in generally have a chemical structure of 12-, 14- or 16-membered macrocyclic group (aglycone) substituted with 1 to 3 substituents such as neutral sugars, deoxy sugars or amino sugars. Macrolides have a wide spectrum of antibacterial activities against for example Pneumococcus spp, Streptococcus spp, Hemophilus influenzae, Staphylococcus aureus, Actinobacillus spp, Pasteurella spp and atypical pathogen such as Mycoplasma, Legionella or Chlamydia that is resistant to other drugs. Consequently, macrolides have been used for the treatment of among others a variety of respiratory tract infections. A variety of macrolides have been discovered or synthesized until now, typically including tylosin represented by the following formula:
  • Tylosin has been used for the treatment of infections of Gram-positive bacterium and Mycoplasma in farm animals.
  • tylosin derivatives typically include among others tilmicosin and tulathromycin (tulathromycin belongs to a different class of compounds) represented by the following formulae, respectively:
  • Tilmicosin and tulathromycin are useful for the treatment of pasteurellosis caused by Gram negative bacillus such as Pasteurella or Mannheimia. They are the most commonly used and important antibiotics in farm animals.
  • Huisgen R. Pure Apple Chem. 1989, 61, 613-628.
  • Huisgen R. In 1,3-Dipolar Cycloaddition Chemistry; Padwa, A., Ed.; Wiley: New York, 1984, 1, 1-176.
  • Staphylococcus spp Streptococcus spp, Enterococcus spp, Neisseria spp, Moraxella spp, Corynebacterium spp, Lactobacillus spp, Bacillus spp, Listeria spp, Erysipelothrix spp, Arcanobacterium spp, Vibrio spp Aeromonas spp, Escherichia spp, Klebsiella spp, Proteus spp, Salmonella spp, Shigella spp, Morganella spp, Citrobacter spp, Enterobacter spp, Serratia spp, Erwinia spp, Yersinia spp, Pseudomonas spp, Alcaligenes spp, Burkholderia spp, Phyllobacterium spp, Acinetobacter spp, Stenotrophomonas s
  • the present compounds can be used in the treatment or prevention of bacterial infections caused by gram-positive bacteria such as staphylococcal, streptococcal, Lactobacillus acidophilus, Corynebacterium diphtheriae, Propionibacterium acnes, Actinomyces bovis, Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus or Clostridium and gram-negative bacteria such as Pasteurella, Mannheimia or Mycoplasma in animals.
  • the present invention provides compounds represented by the formula (Ila):
  • R 11 andR 12 are each independently selected from hydrogen
  • Ci-Ce- ⁇ wherein X is selected from the group consisting of hydroxyl or protected hydroxyl, halogen, and N3,
  • Cl -C6-alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
  • C2-C6-alkenyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
  • C2-C6-alkynyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
  • R 11 and R 12 taken with the nitrogen atom to which they are connected form N3 or a 3- to 7- membered ring which may optionally contain a hetero function selected from the group consisting of - ⁇ -, -NH-, -N(Cl-C6-alkyl)-, -N(aryl) -, -N (heteroaryl)-, -S-, -S(O)- and-S(0) 2 -;C3-C14 cycloalkyl; and wherein R 5 is
  • each Y is independently selected from the group consisting of hydrogen and Cl- C6-alkyl, or the two Y taken with the nitrogen atom to which they are connected form a 3- to 7- membered ring.
  • the present invention provides compounds of said formula (Ila), wherein: R 5 is hydroxy. In another embodiment, the present invention provides compounds of said formula (Ila), wherein:
  • R 11 or R 12 is Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, and wherein preferably
  • R 11 or R 12 is Cl-C6-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and wherein more preferably
  • R 11 or R 12 is Cl-C3-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and wherein even more preferably
  • R 11 or R 12 is Cl-C3-alkyl, substituted with a 1,2,3-triazole substituted at position 4 with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic.
  • the present invention provides compounds of said formula (Ila), wherein: one of R 11 and R 12 is Cl-C6-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and the other one of R 11 and R 12 is
  • Cl-C6-alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; wherein preferably
  • R 11 or R 12 is Cl-C3-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and the other one of Rl 1 and R12 is
  • Cl-C3-alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, wherein even more preferably
  • R 11 and R 12 is Cl-C2-alkyl, substituted with a 1,2,3-triazole substituted at position 4 with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and the other one of R 11 and R 12 is
  • Cl-C2-alkyl optionally substituted with one substituent selected from the group consisting of aryl and substituted aryl.
  • the present invention provides a method for preparing a compound of the formula (Ila):
  • R 1 is as defined for R 11 and R 12 in the formula (Ila) above, and
  • R 2 is C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; or
  • R 1 is as defined for R 11 and R 12 in the formula (Ila) above, and
  • R 2 is C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic
  • R-N3 wherein R is as defined for R 11 or R 12 in the formula (Ila) above, in the presence of a copper catalyst to form a compound of the formula (Ila); or (iii) reacting O-mycaminosyltylonolide (OMT):
  • R 1 is as defined for R 11 and R 12 in the formula (Ila) above, and
  • R 2 is Cl-C6-alkyl, bearing one N3-substituent and being optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; or
  • R 1 is as defined for R 11 and R 12 in the formula (Ila) above, and
  • R 2 is Cl-C6-alkyl, bearing one N3-substituent and being optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic
  • the present invention provides a pharmaceutical or veterinary composition comprising the compound of the present invention.
  • Such composition may be used for the treatment or the prevention of bacterial infections or disorders associated with bacterial infections in animals, which include among others mammal, fish or birds.
  • the pharmaceutical or veterinary composition may include or may be used simultaneously, sequentially or contiguously with one or more other antibiotics.
  • compositions comprising the compound of formula (Ila) as mentioned before.
  • These compositions, as well as the compounds of formula (Ila) as mentioned before, may preferably be used for the treatment of mastitis in non-human mammals, such as cattle, camel, buffalo, goat or sheep, more preferably in ruminants that are used for milk production for human consumption, such as cattle, buffalo, sheep, and goat.
  • the present invention provides uses of the compounds of the present invention for manufacturing a medicament for treatment or prevention of bacterial infections or disorders associated with bacterial infections in animals.
  • the present invention provides compounds according to the embodiments as mentioned before for use as a medicament, preferably the compounds of formula (Ila) as mentioned before.
  • the present invention provides compounds or pharmaceutical or veterinary compositions according to the embodiments as mentioned before for use in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in an animal, preferably the compounds of formula (Ila) as mentioned before.
  • the compounds of the present invention has different chemical structure from tylosin or tilmicosin, while the present compounds may have antibacterial activities similar to or greater than those of tylosin or tilmicosin. Therefore, the compounds of the present invention may be used as a substitute for tylosin or tilmicosin, particularly to treat infections or related disorders caused by tylosin- or tilmicosin-resistant bacteria. Accordingly, the compound of the present invention is useful in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in animals.
  • Cl-C3-alkyl refers to saturated, straight- or branched-chain hydrocarbon radicals containing between one and three, one and six or one and twelve carbon atoms, respectively.
  • C0-C3-alkyl means a bond or Cl-C3-alkyl.
  • Cl-C3-alkyl radicals include methyl, ethyl, propyl and isopropyl
  • C1-C6- alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n- butyl, tert-butyl, neopentyl and n-hexyl
  • examples of Cl-C12-alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl, n-octyl, n-decyl and n-dodecyl.
  • C2-C6-alkenyl refers to straight- or branched-chain hydrocarbon radicals containing between two and six carbon atoms with one or more double bonds in the chain.
  • Examples of C2-C6-alkenyl include, but are not limited to, propenyl, isobutenyl, 1,3-hexadienyl, n- hexenyl and 3-pentenyl.
  • C2-C6-alkynyl or the like, as used herein, refers to straight- or branched-chain hydrocarbon radicals containing between two and six carbon atoms with one or more triple bonds in the chain optionally containing one or more double bond.
  • C2-C6- alkynyl examples include, but are not limited to, propynyl, isopentynyl, 1,3-hexadiynyl, n-hexynyl, 3- pentynyl, and l-hexen-3-ynyl.
  • aryl refers to unsubstituted carbocyclic mono-, di- or tri-cyclic aromatic groups including, but not limited to, phenyl, 1 -or 2-naphthyl, anthracene, phenanthrene and the like.
  • C3-C14-cycloalkyl refer to unsubstitued mono-, di- or tri-cyclic groups where each carbocyclic ring consisting cycloalkyl comprises 3 to 7 carbon atoms, respectively, such as for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • heteroaryl refers to a mono-, di- or tri-cyclic aromatic radical having from five to fourteen ring atoms of which one ring atom is selected from S, O and N; zero, one or more ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
  • heterocycloalkyl refers to a non-aromatic 3-, 4-, 5-, 6-or 7-membered ring or a bi-or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to one or two benzene ring.
  • heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.
  • heterocyclic refers to heterocycloalkyl and heteroaryl.
  • substituted heterocyclic refers to substituted heterocycloallcyl and substituted heteroaryl.
  • substituted aryl refers to an aryl group, as defined herein, substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N0 2 , CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C0 2 -alkyl, C0 2 - aryl, C0 2 -heteroaryl, CONH 2 , CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl-C6- alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC0 2 -alkyl, OC0 2 -aryl, OC0 2 -heteroaryl, OCONH 2 , OCONH- Cl-C6-alkyl, OCONH-aryl,
  • substituted heteroaryl refers to a heteroaryl group as defined herein substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N0 2 , CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C0 2 -alkyl, C0 2 -aryl, C0 2 -heteroaryl, CONH 2 , CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl- C6-alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC0 2 -alkyl, OC0 2 -aryl, OC0 2 -heteroaryl, OCONH 2 , OCONH-Cl-C6-alkyl, OCONH-aryl, OCONH-aryl, OCONH-
  • substituted heterocycloalkyl refers to a heterocycloalkyl group, as defined above, substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N0 2 , CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C0 2 -alkyl, C0 2 -aryl, C0 2 -heteroaryl, CONH 2 , CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl-C6-alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC0 2 -alkyl, OC0 2 -aryl, OC0 2 -heteroaryl, OCONH 2 , OCONH-Cl-C6-alkyl,
  • substituted cycloalkyl refers to a cycloalkyl group, as defined above, substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N0 2 , CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C0 2 -alkyl, C0 2 -aryl, C0 2 -heteroaryl, CONH 2 , CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl- C6-alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC0 2 -alkyl, OC0 2 -aryl, OC0 2 -heteroaryl, OCONH 2 , OCONH-Cl-C6-alkyl,
  • amino includes a group represented by -NH 2 .
  • substituted amino indicates amino groups having one or two substituents in place of one or two hydrogen atoms attached to nitrogen atom of the amino group.
  • “Hydroxy-protecting group” refers to an easily removable group which is known in the art to protect a hydroxyl group against undesirable reaction during synthetic procedures and to be selectively removable.
  • the use of hydroxy-protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure and many such protecting groups are known. See, for example, T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999).
  • hydroxy-protecting groups include, but are not limited to, methylthiomethyl, tert-dimethylsilyl, tert-butyldiphenylsilyl, acyl substituted with an aromatic group and the like.
  • protected-hydroxy refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including, for example, but not limited to, benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups.
  • Aldehyde-protecting group refers to an easily removable group which is known to protect an aldehyde group against undesirable reaction during synthetic procedures and to be selectively removable.
  • aldehyde-protecting groups are well known in the art for protecting aldehyde groups against undesirable reactions during a synthetic procedure and many such protecting groups are known. See, for example, T. H. Greene and P. G, M, Wuts, Protective Groups in Organic Synthesis, op. cit.
  • aldehyde-protecting groups include, but are not limited to, acetals, ketals, O-substituted cyanohydrins, substituted hydrazones, imines and the like.
  • protected aldehyde refers to an aldehyde group protected with an aldehyde protecting group, as defined above, including, for example, but not limited to, dimethyl acetyl, dimethoxy methyl, 1,3- dioxolane, 1,3-dioxane and the like.
  • the compound of the present invention can be prepared, but is not limited to, by any conventional method known to an artisan of ordinary skill, for example according to any one of the methods described below, typically analogous to the method detailed in Examples of the present specification.
  • the preparation of the present compound can be performed typically by using cycloaddition reaction between azide and acetylene derivative, what is called click chemistry (see, for example Kolb, H. C; Finn, M. G.; Sharpless, K. B., Angew. Chem., Int. Ed. 2001, 40, 2004-2021 and Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B., Angew. Chem., Int. Ed. 2002, 41, 2596-2599).
  • click chemistry see, for example Kolb, H. C; Finn, M. G.; Sharpless, K. B., Angew. Chem., Int. Ed. 2001, 40, 2004-2021 and Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B., Angew. Chem., Int. Ed. 2002, 41, 2596-2599.
  • N i3 ⁇ 4-N-R b
  • Ra and Rb indicate any functional groups and LnCu indicates copper catalysis.
  • the click chemistry may be typically characterized by sophisticated functional group selectivity and regio selectivity, mild reaction condition, high yield, and applicability for a wide variety of substituents.
  • R 5 , R 11 and R 12 are as defined above;
  • R 1 is as defined for R 11 and R 12 in the formula (Ha) above, and
  • R 2 is C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; and
  • R 1 is as defined for R 11 and R 12 in the formula (Ha) above, and
  • R 2 is Cl-C6-alkyl, bearing one N3-substituent and being optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; and
  • A is CH2-hydroxy
  • variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein A is CH2-N3 and the other variable groups are as defined in the formula (I); and
  • DPPA diphenylphosphoryl azide
  • NaNs sodium azide
  • A is CH2-R' and R3, R4, R5, R' and R p are as defined above.
  • R5 is R' and A, Rl, R2, R3, R4, R' and R p are as defined above;
  • R5 is hydroxy
  • the other variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein R5 is -N3 and the other variable groups are as defined in the formula (I); and (ii) reacting the resulting compound of the formula (II) wherein R5 is -N3 and the other variable groups are as defined in the formula (I) with an R-C ⁇ CH, wherein R is as defined in the formula (I) above, in the presence of a copper catalyst to form a compound of the formula (II),
  • DPPA diphenylphosphoryl azide
  • NaNs sodium azide
  • R5 is R' and A, R3, R4, R' and R p are as defined above.
  • the starting materials are commercially available or can be easily prepared a compound commercially available according to any know method.
  • A is CH2-hydroxy
  • the starting compounds of formula (II) may, if desired, be halogenized, for example with a halogenating agent such as h or CCLt in the presence of PPI13 in a solvent such as pyridine and/or dichloromethyl at -27 to 40°C, preferably 0°C to rt, so that a compound of formula (II) wherein A is CH2-halo or R5 is halogen is formed.
  • a halogenating agent such as h or CCLt
  • a solvent such as pyridine and/or dichloromethyl at -27 to 40°C, preferably 0°C to rt
  • step (i) in the preparing methods above can be carried out by reacting azide such as diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) with the starting material in the presence of solvent such as THF or DMSO at -27 to 100°C, preferably at 0 to 80°C.
  • azide such as diphenylphosphoryl azide (DPPA) or sodium azide (NaNs)
  • solvent such as THF or DMSO
  • step (ii) and (iv) in the preparing methods for formula (I) and (lib) above can be carried out in a solvent for example water, tert-butyl alcohol, methanol or acetonitrile or combination thereof, preferably in acetonitrile, preferably in the presence of tris[(l-benzyl-lH-l,2,3-triazol-4- yl)methyl] amine (TBTA), in the presence of a copper catalysis for example CuSO r5H20, CuOTf- CeH6, [Cu(NCCH 3 ) 4 ] [PF 6 ] or Cul, preferably Cul at 0 to 100°C, preferably 10 to 40°C, more preferably rt.
  • a solvent for example water, tert-butyl alcohol, methanol or acetonitrile or combination thereof, preferably in acetonitrile, preferably in the presence of tris[(l-benzyl-lH-l,2,3-triazol
  • variable groups are as defined in the formula (I), but A is not -CHO, with a CH ⁇ C-(CH2) n -0- NH2-FIC1 wherein n is an integer from 1 to 3 to form a compound of the formula (III):
  • n is an integer from 1 to 3 and A, R3, R4, R5 and R p are as defined in formula (I), provided that A is not -CHO; and
  • step (ii) reacting the compound of the formula (III) resulting from step (i) or (ii) with an R-N3, wherein R is as defined in formula (I) above, in the presence of a copper catalyst to form a compound of the formula (I):
  • variable groups are as defined in the formula (I), but A is not -CHO can be readily available or prepared according to any conventional process known to the skilled person.
  • the introduction of an acetylene moiety of step (i) can be carried out by reacting a CH ⁇ C-(CH2)n-0-NH2-HCl (wherein n is as defined above) with the starting material in a solvent such as pyridine or methanol or combination thereof, preferably in the combination of pyridine and methanol, at 0 to 80°C, preferably rt to 65°C. If desired, an oxo or hydroxyl group which is desired not to participate in the introduction of an acetylene moiety can be protected by any conventional process.
  • a solvent such as pyridine or methanol or combination thereof, preferably in the combination of pyridine and methanol
  • reaction of step (ii) and (iv) for formula (I) and (lib) can be carried out in solvent, for example water, tert-butyl alcohol, methanol or acetonitrile or combination thereof, preferably in acetonitrile, preferably in the presence of tris[(l-benzyl-lH-l,2,3-triazol-4- yl)methyl] amine (TBTA), in the presence of copper catalyst, for example CuSO r5H20, CuOTf-CeH6, [Cu(NCCH 3 ) 4 ][PF 6 ] or Cul, preferably Cul at 0 to 100°C, preferably 10 to 40°C, more preferably rt.
  • solvent for example water, tert-butyl alcohol, methanol or acetonitrile or combination thereof, preferably in acetonitrile, preferably in the presence of tris[(l-benzyl-lH-l,2,3-triazol-4- yl)methyl]
  • R-N3 and R-C ⁇ CH are commercially available or can be easily prepared by any conventional procedure known to a skilled person.
  • the process steps to synthesize the compounds of the invention can be carried out under reaction conditions that are known per se, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, including, for example, solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g., in the H + form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, for example in a temperature range of from about -100 °C to about 190°C, including, for example, from approximately -80°C to approximately 150°C, for example at from -80 to -60°C, at room temperature, at from -20 to 40°C or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen
  • solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofurane or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N- methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride
  • Such solvent mixtures may also be used in working up, for example by chromatography or partitioning.
  • protecting group only a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention is designated a "protecting group,” unless the context indicates otherwise.
  • the protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as e.g., Science of Synthesis: Houben-Weyl Methods of Molecular Transformation. Georg Thieme Verlag, Stuttgart, Germany. 2005. 41627 pp. (URL: http://www.science- of-synthesis.com (Electronic Version, 48 Volumes)); J. F. W.
  • Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known per se.
  • salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g., the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used.
  • metal compounds such as alkali metal salts of suitable organic carboxylic acids, e.g., the sodium salt of 2-ethylhexanoic acid
  • organic alkali metal or alkaline earth metal compounds such as the corresponding hydroxides, carbonates or hydrogen carbonates, such
  • Acid addition salts of compounds of the present invention are obtained in customary manner, e.g., by treating the compounds with an acid or a suitable anion exchange reagent.
  • Internal salts of compounds of the present invention containing acid and basic salt- forming groups, e.g., a free carboxy group and a free amino group, may be formed, e.g., by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g., with weak bases, or by treatment with ion exchangers.
  • solvates refer to those forms of the compounds according to the invention which, in the solid or liquid state, form a complex by coordination with solvent molecules. Hydrates are a specific form of the solvates in which the coordination is with water. Crystals of the present compounds may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
  • the invention relates also to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
  • This invention also encompasses pharmaceutical or veterinary compositions containing, and methods of treating bacterial infections through administering, pharmaceutically acceptable prodrugs of the compounds of the invention.
  • compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs.
  • Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently bound through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the invention.
  • the amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters.
  • Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115.
  • Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups.
  • Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
  • the compounds of the present invention have valuable pharmacological properties and thus they can be used for the treatment of diseases.
  • the compound of the present invention may be used for the treatment or prevention of bacterial infections or disorders associated with bacterial infections in animals, for example mammals, fish or birds.
  • the term "animal”, “patient” or “subject” as used herein is used interchangeably.
  • the term animal typically includes, but is not limited to animals suffering from, at risk of suffering from, or potentially capable of suffering from a bacterial infection, for example humans, cattle, horses, chickens, pigs, sheep, goats, dogs, apes, cats, mice, rabbits, rats, etc.; especially farm animals such as cattle, pigs and poultry.
  • bacterial infection(s) includes, but is not limited to, bacterial infections that occur in mammals, fish and birds as well as disorders related to bacterial infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention.
  • the compounds of the present invention are useful for treating infections caused by bacteria such as:
  • Staphylococcus spp Streptococcus spp, Enterococcus spp, Neisseria spp, Moraxella spp, Corynebacterium spp, Lactobacillus spp, Bacillus spp, Listeria spp, Erysipelothrix spp, Arcanobacterium spp, Vibrio spp Aeromonas spp, Escherichia spp, Klebsiella spp, Proteus spp, Salmonella spp, Shigella spp, Morganella spp, Citrobacter spp, Enterobacter spp, Serratia spp, Erwinia spp, Yersinia spp, Pseudomonas spp, Alcaligenes spp, Burkholderia spp, Phyllobacterium spp, Acinetobacter spp, Stenotrophomonas s
  • the present compounds can be used in the treatment or prevention of bacterial infections caused by gram-positive bacteria such as staphylococcal, streptococcal, Lactobacillus acidophilus, Corynebacterium diphtheriae, Propionibacterium acnes, Actinomyces bovis, Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus or Clostridium or gram-negative bacteria such as Pasteurella, Mannheimia or Mycoplasma infections in animals.
  • gram-positive bacteria such as staphylococcal, streptococcal, Lactobacillus acidophilus, Corynebacterium diphtheriae, Propionibacterium acnes, Actinomyces bovis, Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus or Clostridium or gram-negative bacteria such as Pasteurella, Mannheimia or Mycoplasma infections in animals.
  • Such bacterial infections and disorders related to such infections include, but are not limited to, the following: acne, rosacea, skin infection, pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Peptostreptococcus spp.
  • Pseudomonas spp. pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheriae, or Actinobacillus haemolyticum
  • respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae
  • saprophyticus or Enterococcus spp. saprophyticus or Enterococcus spp.; urethritis and cervicitis; sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Nesseria gonorrheae; toxin diseases related to infection by S. aureus (food poisoning and Toxic shock syndrome), or Groups A, S.
  • MAC Mycobacterium avium complex
  • gastroenteritis related to infection by Campylobacter jejuni
  • intestinal protozoa related to infection by Cryptosporidium spp., odontogenic infection related to infection by viridans streptococci
  • persistent cough related to infection by Bordetella pertussis
  • gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.
  • atherosclerosis related to infection by Helicobacter pylori or Chlamydia pneumoniae; or the like.
  • bovine respiratory disease related to infection by P. haemolytica., P. multocida, Mycoplasma bovis, or Bordetella spp. cow enteric disease related to infection by E. coli or protozoa (i.e., coccidia, Cryptosporidia, etc.), dairy cow mastitis related to infection by S. aureus, S. uberis, S. agalactiae, S. dysgalactiae, Klebsiella spp., Corynebacterium, or Enterococcus spp.
  • swine enteric disease related to infection by E. coli, Lawsonia intracellularis, Salmonella spp., or Serpulina hyodyisinteriae
  • cow footrot related to infection by Fusobacterium spp.
  • Prevotella spp Other bacterial infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J. P. Sanford at al., "The Sanford Guide To Antimicrobial Therapy," 26th Edition, (Antimicrobial Therapy, Inc., 1996).
  • the compounds of the present invention is especially effective to respiratory diseases such as pasteurellosis caused by Gram negative bacillus such as Pasteurella or Mannheimia in farm animals such as cows.
  • Still further bacterial infections and disorders related to such infections that may be treated or prevented in animals especially by compounds of formula (Ila) as mentioned before include, but are not limited to, mastitis in all non-human milk-producing mammals, such as cattle, camel, buffalo, goat or sheep, and which may be associated with several pathogens including E.
  • the present invention provides a pharmaceutical or veterinary composition comprising any of the compounds of the present invention.
  • the composition may comprise therapeutically effective amount of the compound of the present invention, and if desired one or more pharmaceutically acceptable excipients or carriers.
  • an effective amount of the compound of the invention is that amount necessary or sufficient to treat or prevent a bacterial infection, e.g. prevent the various morphological and somatic symptoms of a bacterial infection, and/or a disease or condition described herein.
  • an effective amount of the compound of the invention is the amount sufficient to treat a bacterial infection in a subject.
  • the effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular compound of the invention. For example, the choice of the compound of the invention can affect what constitutes an "effective amount.”
  • One of ordinary skill in the art would be able to study the factors contained herein and make the determination regarding the effective amount of the compounds of the invention without undue experimentation.
  • the regimen of administration can affect what constitutes an effective amount.
  • the compound of the invention can be administered to the subject either prior to or after the onset of a bacterial infection. Further, several divided dosages, as well as staggered dosages, can be administered daily or sequentially, or the dose can be continuously infused, or can be a bolus injection. Further, the dosages of the compound(s) of the invention can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.
  • Compounds of the invention may be used in the treatment of states, disorders or diseases as described herein, or for the manufacture of pharmaceutical or veterinary compositions for use in the treatment of these diseases. Methods of use of compounds of the present invention in the treatment of these diseases, or pharmaceutical or veterinary preparations comprising compounds of the present invention for the treatment of these diseases are also included in embodiments of the present invention.
  • pharmaceutical or veterinary composition includes preparations suitable for administration to mammals, e.g., farm animals such as cows.
  • mammals e.g., farm animals such as cows.
  • pharmaceutical or veterinary composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals.
  • the carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • Formulations of the present invention include those known in the art.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Methods of preparing these formulations or compositions are also known in the art.
  • treat includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated.
  • the treatment comprises the induction of a bacterial infection, followed by the activation of the compound of the invention, which would in turn diminish or alleviate at least one symptom associated or caused by the bacterial infection being treated.
  • treatment can be diminishment of one or several symptoms of a disorder or complete eradication of a disorder.
  • mastitis refers to inflammation of the mammary gland. Physical, chemical and usually bacteriological changes in the milk and pathological changes in the glandular tissue characterize it. The glandular changes often result in a number of symptomatic conditions such as, discoloration of the milk, the presence of clots and the presence of large numbers of leukocytes. Clinically, mastitis is seen as swelling, heat, pain and induration in the mammary gland often resulting in deformation of the udder. An inflamed udder can be visibly seen or determined through palpation of the udder.
  • the diagnosis of subclinical infections has come to depend largely on indirect tests which depend on the leukocyte content of the milk (flakes, clots, or serous milk), at least 1 bacterium is detected in at least 100 ⁇ L ⁇ of milk from the udder, elevated somatic cell count (SCC) usually higher than 300,000 cells/mL and/or the electrical conductivity of the milk is increased from normal.
  • SCC somatic cell count
  • Prevention of mastitis means preventing the occurrence of the infection. Prevention also includes treatment of cows that do not exhibit any signs of mastitis but are in the presence of other cows that do have at least one sign of mastitis to minimize or prevent the transmission or potential transmission of mastitis from one cow to another.
  • These compounds may be administered to humans and other animals for therapy by any suitable route of administration.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical or veterinary compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical or veterinary compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical or veterinary composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical or veterinary composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • intravenous and subcutaneous doses of the compounds of this invention for a patient when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 1.0 to about 100 mg per kg per day.
  • An effective amount is that amount treats a bacterial infection.
  • the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • a compound of the present invention While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical or veterinary composition.
  • the antibacterial activity by the compounds of the present invention may be measured using a number of assays available in the art.
  • An example of such an assay is the standard minimum inhibitory concentration (MIC) test conducted according to CSLI guidelines or paper disc test conducted according to Examples below.
  • A is selected from the group consisting of:
  • R7 and R8 are each independently selected from hydrogen, Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic or R7 and R8 taken with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain a hetero function selected from the group consisting of -0-, -NH-, -N(Cl-C6-alkyl)-, -N(
  • Rl and R2 are each independently selected from the group consisting of:
  • R3 is selected from the group consisting of:
  • Cl-C6-alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined;
  • C2-C6-alkenyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined; and
  • C2-C6-alkynyl optionally substituted with one or more substitutents selected fron the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined;
  • R4 is -M-Y, where M is:
  • Cl-C6-alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined,
  • C2-C6-alkynyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined,
  • R5 is selected from the group consisting of:
  • R p is hydrogen or a hydroxy protecting group
  • each R' is independently [l,4]-epi-[l ,2,3]-triazoro-R; and where each R is independently selected from the group consisting of:
  • Cl-C9-alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined;
  • At least one of A, Rl and R2 and R5 comprise R'.
  • A is selected from halogen, CH2-N3, hydroxy, CHO, hydroxyCi-6alkyl, haloCi-6alkyl, methyl(3,5-di(Cl- C3-alkyl)-piperidino), CH 2 -R, and -CH 2 -NR7R8;
  • R3 is H
  • R4 is H
  • R5 is selected from hydroxy, N3, halogen, 6-deoxy-2,3-di-0-methyl-b-d-allo-hexapyranosyloxy and R';
  • R' is as defined above;
  • At least one of A, Rl and R2 and R5 comprises R';
  • A is CH 2 -R'or -CH 2 -NR7R8; Rl and R2 taken together are oxo;
  • R3 is H
  • R4 is H
  • R5 is 6-deoxy-2,3-di-0-methyl-b-d-allo-hexapyranosyloxy.
  • A is CHO or methyl(3,5-dimethylpiperidino)or -CH 2 NR7R8;
  • R3 is H
  • R4 is H
  • R5 is R'.
  • R3 is H
  • R4 is H
  • R5 is hydroxy. Furthermore, compounds of said formula (I) are disclosed, wherein;
  • A is CHO, methyl(3,5-dimethylpiperidino), or -CH 2 -NR7R8;
  • R3 is H
  • R4 is H
  • R5 is 6-deoxy-2,3-di-0-methyl-b-d-allo-hexapyranosyloxy.
  • R is preferably selected from the group consisting of
  • A is CH 2 -R' and Rl, R2, R3, R4, R5, R' and R p are as defined above; which method comprises following steps:
  • A is CH2-hydroxy
  • variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein A is CH2-N3 and the other variable groups are as defined in the formula (I); and
  • DPPA diphenylphosphoryl azide
  • NaNs sodium azide
  • A is CH 2 -R' and R3, R4, R5, R' and R p are as defined above.
  • R5 is R' and A, Rl, R2, R3, R4, R' and R p are as defined above;
  • R5 is hydroxy
  • variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein R5 is -N3 and the other variable groups are as defined in the formula (I); and
  • DPPA diphenylphosphoryl azide
  • NaNs sodium azide
  • R5 is R' and A, R3, R4, R and R p are as defined above.
  • variable groups are as defined in the formula (I), but A is not -CHO, with a CH ⁇ C-(CH2) n -0- NH 2 -HC1 wherein n is an integer from 1 to 3 to form a compound of the formula (III):
  • step (ii) reacting the compound of the formula (III) resulting from step (i) or (ii) with an R-N3, wherein R is as defined in formula (I) above, in the presence of a copper catalyst to form a compound of the formula (I):
  • Infrared (IR) absorption spectra were determined by using Horiba FT-210 spectrometer. 3 ⁇ 4 NMR spectra were determined by using JEOL JNM-EX270 (270 MHz), VALIAN-400 NMR System (400 MHz). 13 C NMR spectra were determined by using JEOL JNM-EX270 (67.5 MHz), VARIAN- 400 NMR system (100 MHz).
  • TLC thin-layer chromatography
  • Tylosin (20. Og, 21.8 mmol) was dissolved in 0.2N HCl aq. (340 mL) and then the mixture was stirred at 35°C for 2 hours. After confirming complete consumption of the starting material, the reaction mixture was neutralized by adding IN NaOH aq., extracted with CHCI3 and dried over Na2S04. The solvent was removed under reduced-pressure to obtain quantitative amount of desmycosin (YT6).
  • the step (5) above was repeated to obtain the 20-triazole-20- deoxodesmycosins, which are shown below.
  • Tylosin (9.16 g, 10.0 mmol) was dissolved to 0.5 M TFA solution (300 mL) and then the mixture was stirred for 5 hours at 100°C. After confirming complete consumption of the starting material, the reaction mixture was neutralized by adding NaHC03 sat. aq., extracted with CHCI3 and dried over Na2S04. The solvent was removed under reduced-pressure. The resulting products were purified by flash column chromatography to obtain YT106 (Yield: 39%). (2) Preparation of 23-azido-23-deoxo-5-Q-mycaminosyltylonolide (YT107)
  • YT13 (0.5 g, 0.56 mmol) was dissolved in HBr (3.0 niL) and then the mixture was stirred for 30 minutes at 50°C. After confirming complete consumption of the starting material, the reaction mixture was neutralized by adding NaHC03 sat. aq., extracted with CHCI3 and dried over Na2SO i. The solvent was removed under reduced pressure. The resulting products were purified by flash column chromatography to obtain YTl 12 (Yield: 39%).
  • YT711 (100.0 mg, 0.138 mmol) with 3-azidoquinoline (30.4 mg, 0.179 mmol) was converted to YT709 (113.9 mg, 92%) as a colorless solid.
  • YT650 (100.0 mg, 0.154 mmol) with 6-azidoquinoline (39.1 mg, 0.230 mmol) was converted to YT710 (115.3 mg, 91%) as a pale yellow solid.
  • YT615 (100.0 mg, 0.150 mmol) with 4-ethynylbiphenyl (53.5 mg, 0.30 mmol) was converted to YT721 (79.6 mg, 63%) as a colorless solid.
  • YT712 (100.0 mg, 0.157 mmol) with 3-azidoquinoline (40.1 mg, 0.236 mmol) was converted to YT739 (97.9 mg, 77%) as a colorless solid.
  • YT646 (100.0 mg, 0.154 mmol) with 5-azidoquinoline (39.1 mg, 0.230 mmol) was converted to YT743 (113.2 mg, 90%) as a pale yellow solid.
  • YT712 (100.0 mg, 0.157 mmol) with 6-azidonaphthalene (40.1 mg, 0.236 mmol) was converted to YT745 (100.2 mg, 79%) as a colorless solid.
  • YT768 a solution of YT768 (80.0 mg, 85.9 ⁇ ) in anhydrous acetonitrile (1.1 mL) was added dimethylamine (40 wt% in water, 0.8 mL). The mixture was heated in a microwave reactor at 80°C for 1 hour. The solvent mixture was concentrated in vacuo, and the residue was purified by flash column chromatography on silica gel (CHCl 3 /MeOH/NH 3 , 60/1/0.15) to give YT770 (69.2 mg, 95%) as a pale yellow solid.
  • M.hemolytica KB345 (Tilmicosin-sensitivity strain) and M.hemolytica KB346 (Tilmicosin- low sensitivity strain) were provided.
  • KB 345 strain stored at -80 °C was seeded to BHIB agar medium
  • a paper disc (ADVANTEC, ⁇ :6 mm) was impregnated with a solution of test compound and dried under reduced pressure.
  • step 3 To a melted BHIB agar medium was inoculated 1% of the broth obtained from step 1) above to prepare a test plate. After the medium set, the paper disc prepared in step 2) above was put on the plate and it was incubated at 37°C.
  • Micrococcus luteus ATCC9341 (1), Bacillus subtilis ATCC663 (s), Escherichia coli NIHJ (c), Xanthomonas campestris KB88 (X), Mucor racemosus IFO 4581 (Mu) and Candida albicans ATCC 64548 (Ca).
  • Bacillus subtilis ATCC6633 was incubated in Davis synthetic medium and then the seed broth was combined with the medium in the ratio of 1 :99 to obtain a test plate.
  • Micrococcus luteus ATCC9341, Escherichia coli NIHJ and Xanthomonas campestris KB88 were respectively incubated in Nutrient agar medium and inoculated at 0.2%., 0.5% and 1.0%.
  • Mucor racemosus IFO 4581 and Candida albicans ATCC 64548 were respectively incubated in GY agar medium and then inoculated at 0.3%> and 0.2%>.
  • a paper disc (ADVANTEC, ⁇ :6 mm) was impregnated with a solution of test compound and dried under reduced pressure. The paper disc was put on the test plate and it was incubated for 24 hours at 37°C. After incubation, the inhibition zone diameter and clarity (A to E) were determined.
  • MICs Minimal inhibitory concentrations were determined against the most prevalent pathogens in cattle (Mannheimia Haemolytica, 3 isolates) and swine (A. pleuropneumoniae, 6 isolates). The results are summarized in Table 7.
  • aureus Newbould is an isolate which was isolated from a clinical case of bovine mastitis and which also causes typical mastitis infection in dairy cattle upon experimental, intramammary infection.
  • compound YT709 was instilled into the infected glands.
  • Different intramammary dosages of YT709 were tested and their efficacy compared to an infected, untreated control group.
  • Fourteen hours after intramammary application of YT709 the glands of the treated and untreated mice were removed, homogenized and the number of S. aureus bacteria counted in 10-fold dilutions of the homogenized glands. The mean S.
  • aureus count of 8 untreated glands was 10 8'64 (8.64 loglO) bacteria.
  • the mean S. aureus count in 6 glands that had been treated with 200 microgram YT709 was lO 5 10 bacteria (5.10 log 10). Hence in the glands treated with 200 microgram YT709 the number of bacteria was reduced about 3500 fold.
  • the mean S. aureus count in the 5 glands that had been treated with 400 microgram YT709 was lO 2 34 bacteria (2.34 loglO). Hence in the glands treated with 400 microgram YT-709 the number of bacteria was reduced about two million fold. In the mice from which the lactating glands had been treated with 400 microgram YT709, S. aureus bacteria could not be counted anymore in measurable numbers and hence in 2 out of 5 glands the infection was cleared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to new macrolide derivatives, in particular new tylosin derivatives of the formula (Ila), a pharmaceutical or veterinary composition comprising the derivatives; a method for preparation thereof; a method for treating and/or preventing bacterial infections in an animal, wherein the method comprises administering the derivatives or the composition; and a use of the derivatives for the manufacture of medicaments for treating and/or preventing bacterial infections in an animal.

Description

TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF
BACKGROUND OF THE INVENTION
The present invention relates to new macrolide derivatives, in particular new tylosin derivatives; a pharmaceutical or veterinary composition comprising any of the derivatives; a method for preparation thereof; a method for treating and/or preventing bacterial infections in an animal, wherein the method comprises administering any of the derivatives or the composition; and a use of the derivatives for the manufacture of medicaments for treating and/or preventing bacterial infections in an animal.
Macrolides in generally have a chemical structure of 12-, 14- or 16-membered macrocyclic group (aglycone) substituted with 1 to 3 substituents such as neutral sugars, deoxy sugars or amino sugars. Macrolides have a wide spectrum of antibacterial activities against for example Pneumococcus spp, Streptococcus spp, Hemophilus influenzae, Staphylococcus aureus, Actinobacillus spp, Pasteurella spp and atypical pathogen such as Mycoplasma, Legionella or Chlamydia that is resistant to other drugs. Consequently, macrolides have been used for the treatment of among others a variety of respiratory tract infections. A variety of macrolides have been discovered or synthesized until now, typically including tylosin represented by the following formula:
Figure imgf000002_0001
mycinose
Tylosin has been used for the treatment of infections of Gram-positive bacterium and Mycoplasma in farm animals. In order to further expand the spectrum of tylosin and to improve its oral bioavailability, a number of tylosin derivatives have been tested. Examples of such tylosin derivatives typically include among others tilmicosin and tulathromycin (tulathromycin belongs to a different class of compounds) represented by the following formulae, respectively:
Figure imgf000003_0001
Tilmicosin and tulathromycin are useful for the treatment of pasteurellosis caused by Gram negative bacillus such as Pasteurella or Mannheimia. They are the most commonly used and important antibiotics in farm animals.
However, new antibiotics are inextricably associated with the emergence of resistant bacteria. Accordingly, there is still a need to provide new antibiotics.
The backgrounds may be reflected in the following Patent and Non-patent References:
Patent References:
Figure imgf000003_0002
Non-patent References:
Woodward, R. B., Angew. Chem. 1957, 69, 50-58.
Brockmann, H.; Henkel, W. Naturwissenshaften. 1950, 37, 138.
Pinnert-Sindico, S.; Ninet, L.; Preud'homme, J.; Cosar, C. Rhone-Poulenc Research Labs., Paris, Antibiotics Ann. 1955, 2, 1954-1955.
Hansen, J. L.; Ippolito, J.A.; Ban, N.; Nissen, P.; Moore, P. B.; Steitz, T. A. Molecular Cell. 2002, 10, 111.
Ducruix, A.; Pascard, C; Nakagawa, A.; Omura, S. J. Chem. Soc. Chem. Commun. 1976, 947.
Morin, R. B.; Gorman, M.; Hamill, R. L. Tetrahedron Lett. 1970, 11, 4737-4740.
Omura, S.; Nakagawa, A.; Neszmelyi, A.; Gero, S. D.; Sepulcre, A. M.; Piriou, F.; Lukacs, G. J. Am. Chem. Soc. 1975, 97, 4001-4009.
McGuire, J. M. Antibiot. Chemother. 1961, 11, 320-327.
Debono, M.; Kirst, H. A.; Omura, S. J. Antibiot. 1989, 42, 1253-1267.
Shokichi Nakajima: Resistant to the drugs - fight against infections-, Maruzen, Tokyo (2000), Cattle death loss: the National Statistics Service (NASS). United State department of Agriculture, May, 5 (2006)
Rogert A. Smith: Impact of disease on feedlot performance: A review. J. Anim. Sci. 1998, 76, 276-274. Maina, H.; John, D. B.; Ben A. FEMS Microbiol. Lett. 2006, 256, 1-10.
Yasutomo Arashima: Misunderstanding of " pasteurellosis" in Japan.
Kolb, H. C; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int. Ed. 2001, 40, 2004-2021.
Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2596-
2599.
a) Huisgen, R. Pure Apple Chem. 1989, 61, 613-628. b) Huisgen, R. In 1,3-Dipolar Cycloaddition Chemistry; Padwa, A., Ed.; Wiley: New York, 1984, 1, 1-176.
a) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2596-2599.
Macrolide antibiotics. Chemistry, biology, and practice. Edited by Omura, S. Academical Press, Inc., Orlando, FL 32887. 1984.
Hirose, T.; Sunazuka, T.; Noguchi, Y.; Yamaguchi, Y.; Hanaki, H.; Sharpless, K. B.; Omura, S. Heterocycles, 2006, 69, 55-61.
Kirst, H. A.; Toth, J. E.; Debono, M.; Willard, K. E.; Truedell, B. A.; Ott, J. L.; Counter, F. T.; Felty- Duckworth, A. M.; Pekarek, R. S. J. Med. Chem. 1988, 31, 1631-1641.
Mereu, A.; Moriggi, E.; Napoletano, M.; Regazzoni, C; Manfredini, S.; Mercurio, T. P.; Pellacini, F. Bioorg. Med. Chem. Lett. 2006, 16, 5801-5804.
Rostovtsev, V. V.; Green, L. G.; Forkin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2597. Chan, T. R.; Hilgraf, R.; Sharpless, K. B.; Fokin, V. V. Org. Lett. 2004, 6, 2853-2855.
Noboru Kagei: Journal of preventive medicine, 1985, 199, 32-33.
Yoshio Ueno, Satoshi Omura: "Microbial Chemistry, 2nd. edition", Nankodo (1986).
Tsuyoshi Yamada: "Fight between bacterium and human", Ishiyaku Publishers, Inc.
Satoshi Omura, Ruiko Oiwa: Chemistry and Biology, 1982, 20, 10-12.
Cassinelli, G.; Cotta, G.; D'Amico, G.; Delia, B. C; Grein, A.; Mazzoleni, R.; Ricciardi, M. L.; Tintinelli, R. Arch. Mikrobiol. 1970, 70, 197-210.
Bruna, D. C; Ricciardi, M. L.; Sanfilippo, A. Antimicrob. Agents. Chemother. 1973, 3, 708-710.
Hamill, R. L.; Hoehn, M. M. J. Antibiot. 1964, 17, 100-103.
Probst, G. W.; Hoehn, M. M.; Woods, B. L. Antimicrob. Agents. Chemother. 1966, 789-795.
Haneisi, T.; Arai, M.; Kitano, N.; Yamamoto, S. J. Antibiot. 1974, 27, 339-342.
Masatoshi Inukai, Hiroshi Mishima: Current Chemistry special 9 "Advanced antibiotics", Tokyo Kagakudojin, 1987, 37-43.
a) Omura, S.; Otoguro, K.; Imamura, N.; Huga, H.; Takahashi, Y.; Masuma, R., Tanaka, Y.; Tanaka, H.; Xue-hui, S.; En-tai, Y. J. Antibio, 1987, 40, 623-629. b) Imamura, N.; Kuga, H.; Otoguro, K.; Tanaka, H.; Omura, S. J. Antibio. 1989, 42, 156-158.
Giencke, W.; Ort, O.; Stark, H. Liebigs. Ann. Chem. 1989. 671-676.
Moss, R. A.; Landon, M. J.; Luchter, K. M.; Mamantov, A. J. Am. Chem. Soc. 1972, 94, 4392-4394. Tsuzuki, K.; Yan, F.; Otoguro, K.; Omura, S. J. Antibiot. 1991, 44, 774-784.
Kar, A.; Argade, N. P. Tetrahedron, 2003, 59, 2991.
Nam, N. H.; Kim, Y.; You, Y. J.; Hong, D. H.; Kim, H. M.; Ahn, B. Z. Bioorg. Med. Chem. Lett. 2002, 12, 1955-1958.
Naora, H.; Ohnuki, T.; Nakamura, A. Bull. Chem. Soc. Jpn. 1988, 61, 993-994. Thakkalapally, A.; Benin, V. Tetrahedron. 2005, 61, 4939-4948. SUMMARY OF THE INVENTION
The object of the present invention is to provide new chemical entities effective in the treatment or prevention of infections in animals caused by bacteria such as:
Staphylococcus spp, Streptococcus spp, Enterococcus spp, Neisseria spp, Moraxella spp, Corynebacterium spp, Lactobacillus spp, Bacillus spp, Listeria spp, Erysipelothrix spp, Arcanobacterium spp, Vibrio spp Aeromonas spp, Escherichia spp, Klebsiella spp, Proteus spp, Salmonella spp, Shigella spp, Morganella spp, Citrobacter spp, Enterobacter spp, Serratia spp, Erwinia spp, Yersinia spp, Pseudomonas spp, Alcaligenes spp, Burkholderia spp, Phyllobacterium spp, Acinetobacter spp, Stenotrophomonas spp, Haemophilus spp, Actinobacillus spp, Bordetella spp, Pasteurella spp, Brucella spp, Campylobacter spp, Capnytophaga spp, Francisella spp, Helicobacter spp, Legionella spp, Mycoplasma spp, Ureaplasma spp, Bartonella spp, Chlamydia spp, Coxiella spp, Ehrlichia spp, Rickettsia spp, Borrelia spp, Leptospira spp, Treponema spp, Brachyspira spp, Veillonella spp, Peptostreptococcus spp, Peptococcus spp, Bacteroides spp, Porphyromonas spp, Prevotella spp, Fusobacterium spp, Clostridium spp, Actinomyces spp, Propionibacterium spp, Eubacterium spp, Lactobacillus spp, Bifidobacterium spp.
More specifically the present compounds can be used in the treatment or prevention of bacterial infections caused by gram-positive bacteria such as staphylococcal, streptococcal, Lactobacillus acidophilus, Corynebacterium diphtheriae, Propionibacterium acnes, Actinomyces bovis, Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus or Clostridium and gram-negative bacteria such as Pasteurella, Mannheimia or Mycoplasma in animals. In one embodiment, the present invention provides compounds represented by the formula (Ila):
Figure imgf000007_0001
or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof;
wherein, R11 andR12 are each independently selected from hydrogen;
CHO;
Ci-Ce-Χ, wherein X is selected from the group consisting of hydroxyl or protected hydroxyl, halogen, and N3,
CN;
Cl -C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
C3-C14-cycloalkyl;
substituted C3-C14-cycloalkyl;
aryl;
substituted aryl;
heterocyclic;
substituted heterocyclic;
or R11 and R12 taken with the nitrogen atom to which they are connected form N3 or a 3- to 7- membered ring which may optionally contain a hetero function selected from the group consisting of - Ο-, -NH-, -N(Cl-C6-alkyl)-, -N(aryl) -, -N (heteroaryl)-, -S-, -S(O)- and-S(0)2-;C3-C14 cycloalkyl; and wherein R5 is
hydrogen;
hydroxyl;
protected hydroxyl;
halogen;
-N3; or
N-Y2, wherein each Y is independently selected from the group consisting of hydrogen and Cl- C6-alkyl, or the two Y taken with the nitrogen atom to which they are connected form a 3- to 7- membered ring.
In a further embodiment, the present invention provides compounds of said formula (Ila), wherein: R5 is hydroxy. In another embodiment, the present invention provides compounds of said formula (Ila), wherein:
at least R11 or R12 is Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, and wherein preferably
at least R11 or R12 is Cl-C6-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and wherein more preferably
at least R11 or R12 is Cl-C3-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and wherein even more preferably
at least R11 or R12 is Cl-C3-alkyl, substituted with a 1,2,3-triazole substituted at position 4 with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic.
In still another embodiment the present invention provides compounds of said formula (Ila), wherein: one of R11 and R12 is Cl-C6-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and the other one of R11 and R12 is
hydrogen or
Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; wherein preferably
one of R11 or R12 is Cl-C3-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and the other one of Rl 1 and R12 is
hydrogen or
Cl-C3-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, wherein even more preferably
one of R11 and R12 is Cl-C2-alkyl, substituted with a 1,2,3-triazole substituted at position 4 with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic, and the other one of R11 and R12 is
hydrogen or
Cl-C2-alkyl, optionally substituted with one substituent selected from the group consisting of aryl and substituted aryl.
In another embodiment, the present invention provides a method for preparing a compound of the formula (Ila):
Figure imgf000009_0001
(Ila) wherein R5, R11 and R12 are as defined above;
which method comprises at least one of the following steps following steps (i), (ii), (iii) and/or (iv): (i) reacting O-mycaminosyltylonolide (OMT):
Figure imgf000010_0001
with an amine of the general formula NR R to form a compound of the following formula (lib)
Figure imgf000010_0002
wherein
R1 is as defined for R11 and R12 in the formula (Ila) above, and
R2 is C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; or
(ii) reacting the resulting compound of the formula (lib),
wherein
R1 is as defined for R11 and R12 in the formula (Ila) above, and
R2 is C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic
with an R-N3, wherein R is as defined for R11 or R12 in the formula (Ila) above, in the presence of a copper catalyst to form a compound of the formula (Ila); or (iii) reacting O-mycaminosyltylonolide (OMT):
Figure imgf000011_0001
with an amine of the general formula NR R to form a compound of the following formula (lib)
Figure imgf000011_0002
wherein
R1 is as defined for R11 and R12 in the formula (Ila) above, and
R2 is Cl-C6-alkyl, bearing one N3-substituent and being optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; or
(iv) reacting the resulting compound of the formula (lib), wherein
R1 is as defined for R11 and R12 in the formula (Ila) above, and
R2 is Cl-C6-alkyl, bearing one N3-substituent and being optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic
with an R-C≡CH, wherein R is as defined for R11 or R12 in the formula (Ila) above, in the presence of a copper catalyst to form a compound of the formula (Ila). In further embodiment, the present invention provides a pharmaceutical or veterinary composition comprising the compound of the present invention. Such composition may be used for the treatment or the prevention of bacterial infections or disorders associated with bacterial infections in animals, which include among others mammal, fish or birds. The pharmaceutical or veterinary composition may include or may be used simultaneously, sequentially or contiguously with one or more other antibiotics.
Preferred in this context are pharmaceutical or veterinary compositions comprising the compound of formula (Ila) as mentioned before. These compositions, as well as the compounds of formula (Ila) as mentioned before, may preferably be used for the treatment of mastitis in non-human mammals, such as cattle, camel, buffalo, goat or sheep, more preferably in ruminants that are used for milk production for human consumption, such as cattle, buffalo, sheep, and goat.
In further embodiment, the present invention provides uses of the compounds of the present invention for manufacturing a medicament for treatment or prevention of bacterial infections or disorders associated with bacterial infections in animals.
In still further embodiments, the present invention provides compounds according to the embodiments as mentioned before for use as a medicament, preferably the compounds of formula (Ila) as mentioned before.
In yet another embodiments, the present invention provides compounds or pharmaceutical or veterinary compositions according to the embodiments as mentioned before for use in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in an animal, preferably the compounds of formula (Ila) as mentioned before.
The compounds of the present invention has different chemical structure from tylosin or tilmicosin, while the present compounds may have antibacterial activities similar to or greater than those of tylosin or tilmicosin. Therefore, the compounds of the present invention may be used as a substitute for tylosin or tilmicosin, particularly to treat infections or related disorders caused by tylosin- or tilmicosin-resistant bacteria. Accordingly, the compound of the present invention is useful in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in animals.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The terms as used herein have the meaning as defined below or as understood by an artisan of ordinary skill in fields of organic chemistry, biochemistry, medical sciences, pharmaceutical sciences, bacteriology and the like.
The terms "Cl-C3-alkyl", "Cl-C6-alkyl", "Cl-C12-alkyl" or the like, as used herein, refer to saturated, straight- or branched-chain hydrocarbon radicals containing between one and three, one and six or one and twelve carbon atoms, respectively. The term "C0-C3-alkyl" means a bond or Cl-C3-alkyl. Examples of Cl-C3-alkyl radicals include methyl, ethyl, propyl and isopropyl, and examples of C1-C6- alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n- butyl, tert-butyl, neopentyl and n-hexyl, and examples of Cl-C12-alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl, n-octyl, n-decyl and n-dodecyl. The term "C2-C6-alkenyl" or the like, as used herein, refers to straight- or branched-chain hydrocarbon radicals containing between two and six carbon atoms with one or more double bonds in the chain. Examples of C2-C6-alkenyl include, but are not limited to, propenyl, isobutenyl, 1,3-hexadienyl, n- hexenyl and 3-pentenyl. The term "C2-C6-alkynyl" or the like, as used herein, refers to straight- or branched-chain hydrocarbon radicals containing between two and six carbon atoms with one or more triple bonds in the chain optionally containing one or more double bond. Examples of C2-C6- alkynyl include, but are not limited to, propynyl, isopentynyl, 1,3-hexadiynyl, n-hexynyl, 3- pentynyl, and l-hexen-3-ynyl.
The term "aryl", as used herein, refers to unsubstituted carbocyclic mono-, di- or tri-cyclic aromatic groups including, but not limited to, phenyl, 1 -or 2-naphthyl, anthracene, phenanthrene and the like.
The term, "C3-C14-cycloalkyl", as used herein refer to unsubstitued mono-, di- or tri-cyclic groups where each carbocyclic ring consisting cycloalkyl comprises 3 to 7 carbon atoms, respectively, such as for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. The terms "halo" and "halogen", as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine.
The term "heteroaryl", as used herein, refers to a mono-, di- or tri-cyclic aromatic radical having from five to fourteen ring atoms of which one ring atom is selected from S, O and N; zero, one or more ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
The term "heterocycloalkyl", as used herein, refers to a non-aromatic 3-, 4-, 5-, 6-or 7-membered ring or a bi-or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocyclic rings may be fused to one or two benzene ring. Representative heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.
The term "heterocyclic", as used herein, refers to heterocycloalkyl and heteroaryl.
The term "substituted heterocyclic", as used herein, refers to substituted heterocycloallcyl and substituted heteroaryl.
The term "substituted aryl", as used herein refers to an aryl group, as defined herein, substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N02, CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C02-alkyl, C02- aryl, C02-heteroaryl, CONH2, CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl-C6- alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC02-alkyl, OC02-aryl, OC02-heteroaryl, OCONH2, OCONH- Cl-C6-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(0)-Cl-C6-alkyl, NHC(0)-aryl, NHC(O)- heteroaryl, NHC02-alkyl, NHC02-aryl, NHC02-heteroaryl, NHCONH2, NHCONH-Cl-C6-alkyl, NHCONH-aryl, NHCONH-heteroaryl, S02-Cl-C6-alkyl, S02-aryl, S02-heteroaryl, S02NH2, S02NH- Cl-C6-alkyl, S02NH-aryl, S02NH-heteroaryl, Cl-C6-alkyl, C3-C7-cycloalkyl, CF3, CH2CF3, CH2C12, CH2OH, CH2CH2OH, CH2NH2, CH2S02CH3, aryl, substituted aryl, heteroaryl, substituted heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, Cl-C6-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, Cl-C3-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl- thio, Cl-C6-alkyl-thio, or methylthiomethyl.
The term "substituted heteroaryl", as used herein refers to a heteroaryl group as defined herein substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N02, CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C02-alkyl, C02-aryl, C02-heteroaryl, CONH2, CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl- C6-alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC02-alkyl, OC02-aryl, OC02-heteroaryl, OCONH2, OCONH-Cl-C6-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(0)-Cl-C6-alkyl, NHC(0)-aryl, NHC(0)-heteroaryl, NHC02-alkyl, NHC02-aryl, NHC02-heteroaryl, NHCONH2, NHCONH-C 1 -C6- alkyl, NHCONH-aryl, NHCONH-heteroaryl, S02-Cl-C6-alkyl, S02-aryl, S02-heteroaryl, S02NH2, S02NH-Cl-C6-alkyl, S02NH-aryl, S02NH-heteroaryl, Cl-C6-alkyl, C3-C7-cycloallcyl, CF3, CH2CF3, CH2C12, CH2OH, CH2CH2OH, CH2NH2, CH2S02CH3, aryl, heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, Cl-C6-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, Cl-C3-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl-thio, Cl-C6-alkyl-thio, or methylthiomethyl.
The term "substituted heterocycloalkyl", as used herein, refers to a heterocycloalkyl group, as defined above, substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N02, CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C02-alkyl, C02-aryl, C02-heteroaryl, CONH2, CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl-C6-alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC02-alkyl, OC02-aryl, OC02-heteroaryl, OCONH2, OCONH-Cl-C6-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(0)-Cl-C6-alkyl, NHC(O)- aryl, NHC(0)-heteroaryl, NHC02-alkyl, NHC02-aryl, NHC02-heteroaryl, NHCONH2, NHCONH-C 1- C6-alkyl, NHCONH-aryl, NHCONH-heteroaryl, S02-Cl-C6-alkyl, S02-aryl, S02-heteroaryl, S02NH2, S02NH-Cl-C6-alkyl, S02NH-aryl, S02NH-heteroaryl, Cl-C6-alkyl, C3-C7-cycloallcyl, CF3, CH2CF3, CH2C12, CH2OH, CH2CH2OH, CH2NH2, CH2S02CH3, aryl, heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, Cl-C6-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, Cl-C3-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl-thio, Cl-C6-alkyl-thio, or methylthiomethyl.
The term "substituted cycloalkyl", as used herein, refers to a cycloalkyl group, as defined above, substituted by independent replacement of one or more of the hydrogen atoms therein with, for example, but not limited to, F, CI, Br, I, OH, N02, CN, C(0)-Cl-C6-alkyl, C(0)-aryl, C(0)-heteroaryl, C02-alkyl, C02-aryl, C02-heteroaryl, CONH2, CONH-Cl-C6-alkyl, CONH-aryl, CONH-heteroaryl, OC(0)-Cl- C6-alkyl, OC(0)-aryl, OC(0)-heteroaryl, OC02-alkyl, OC02-aryl, OC02-heteroaryl, OCONH2, OCONH-Cl-C6-alkyl, OCONH-aryl, OCONH-heteroaryl, NHC(0)-Cl-C6-alkyl, NHC(0)-aryl, NHC(0)-heteroaryl, NHC02-alkyl, NHC02-aryl, NHC02-heteroaryl, NHCONH2, NHCONH-C 1 -C6- alkyl, NHCONH-aryl, NHCONH-heteroaryl, S02-Cl-C6-alkyl, S02-aryl, S02-heteroaryl, S02NH2, S02NH-Cl-C6-alkyl, S02NH-aryl, S02NH-heteroaryl, Cl-C6-alkyl, C3-C7-cycloallcyl, CF3, CH2CF3, CH2C12, CH2OH, CH2CH2OH, CH2NH2, CH2S02CH3, aryl, heteroaryl, benzyl, benzyloxy, aryloxy, heteroaryloxy, Cl-C6-alkoxy, methoxymethoxy, methoxyethoxy, amino, benzylamino, arylamino, heteroarylamino, Cl-C3-alkyl-amino, thio, aryl-thio, heteroarylthio, benzyl-thio, Cl-C6-alkyl-thio, or methylthiomethyl.
The term "amino" includes a group represented by -NH2. The term "substituted amino" indicates amino groups having one or two substituents in place of one or two hydrogen atoms attached to nitrogen atom of the amino group. The term "azide" means a group represented by -N3, which may comprise -N-N≡N or -N=N=N.
"Hydroxy-protecting group", as used herein, refers to an easily removable group which is known in the art to protect a hydroxyl group against undesirable reaction during synthetic procedures and to be selectively removable. The use of hydroxy-protecting groups is well known in the art for protecting groups against undesirable reactions during a synthetic procedure and many such protecting groups are known. See, for example, T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxy-protecting groups include, but are not limited to, methylthiomethyl, tert-dimethylsilyl, tert-butyldiphenylsilyl, acyl substituted with an aromatic group and the like. The term "protected-hydroxy", refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including, for example, but not limited to, benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups. "Aldehyde-protecting group", as used herein, refers to an easily removable group which is known to protect an aldehyde group against undesirable reaction during synthetic procedures and to be selectively removable. The use of aldehyde-protecting groups is well known in the art for protecting aldehyde groups against undesirable reactions during a synthetic procedure and many such protecting groups are known. See, for example, T. H. Greene and P. G, M, Wuts, Protective Groups in Organic Synthesis, op. cit. Examples of aldehyde-protecting groups include, but are not limited to, acetals, ketals, O-substituted cyanohydrins, substituted hydrazones, imines and the like. The term "protected aldehyde" refers to an aldehyde group protected with an aldehyde protecting group, as defined above, including, for example, but not limited to, dimethyl acetyl, dimethoxy methyl, 1,3- dioxolane, 1,3-dioxane and the like.
The compound of the present invention can be prepared, but is not limited to, by any conventional method known to an artisan of ordinary skill, for example according to any one of the methods described below, typically analogous to the method detailed in Examples of the present specification.
The preparation of the present compound can be performed typically by using cycloaddition reaction between azide and acetylene derivative, what is called click chemistry (see, for example Kolb, H. C; Finn, M. G.; Sharpless, K. B., Angew. Chem., Int. Ed. 2001, 40, 2004-2021 and Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B., Angew. Chem., Int. Ed. 2002, 41, 2596-2599). The mechanism of the reaction is represented by the following scheme A: 1
Figure imgf000019_0001
N=i¾-N-Rb
(A) wherein Ra and Rb indicate any functional groups and LnCu indicates copper catalysis. The click chemistry may be typically characterized by sophisticated functional group selectivity and regio selectivity, mild reaction condition, high yield, and applicability for a wide variety of substituents.
One embodiment for a method for preparing a compound of the formula (Ila):
Figure imgf000019_0002
wherein R5, R11 and R12 are as defined above;
which method comprises following steps :
(i) reacting O-mycaminosyltylonolide (OMT):
Figure imgf000020_0001
with an amine of the general formula NR'R2 to form a compound of the following formula (lib)
Figure imgf000020_0002
wherein
R1 is as defined for R11 and R12 in the formula (Ha) above, and
R2 is C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; and
(ii) reacting the resulting compound of the formula (lib) with an R-N3, wherein R is as defined for R11 or R12 in the formula (Ila) above, in the presence of a copper catalyst to form a compound of the formula (Ila); or
(iii) reacting O-mycaminosyltylonolide (OMT):
Figure imgf000020_0003
with an amine of the general formula NR'R2 to form a compound of the following formula (lib)
Figure imgf000021_0001
R1 is as defined for R11 and R12 in the formula (Ha) above, and
R2 is Cl-C6-alkyl, bearing one N3-substituent and being optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic; and
(iv) reacting the resulting compound of the formula (lib) with an R-C≡CH, wherein R is as defined for R11 or R12 in the formula (Ila) above, in the presence of a copper catalyst to form a compound of the formula (Ila).
The starting compound of the formula:
Figure imgf000021_0002
can be prepared by performing, for example following sub-steps:
(a) deglycosylation of tylosin under acidic condition, for example in the presence of TFA aq. or HBr; and
(b) optionally converting the remaining functional groups to desired substituents according to any conventional process.
Figure imgf000022_0001
myronose
One example for a method for preparing a compound of the formula (I):
Figure imgf000022_0002
( I I )
wherein,
A is CH2-hydroxy; and
the other variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein A is CH2-N3 and the other variable groups are as defined in the formula (I); and
(ii) reacting the resulting compound of the formula (II) wherein A is CH2-N3 and the other variable groups are as defined in the formula (I) with an R-C≡CH, wherein R is as defined in the formula (I) above, in the presence of a copper catalyst to form a compound of the formula (II),
wherein A is CH2-R' and R3, R4, R5, R' and Rp are as defined above.
Further example, for a method for preparing a compound of the formula (I):
Figure imgf000023_0001
CD
wherein R5 is R' and A, Rl, R2, R3, R4, R' and Rp are as defined above;
which method comprises following steps:
(i) reacting a compound of the formula (II):
Figure imgf000023_0002
( I I )
wherein,
R5 is hydroxy; and
the other variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein R5 is -N3 and the other variable groups are as defined in the formula (I); and (ii) reacting the resulting compound of the formula (II) wherein R5 is -N3 and the other variable groups are as defined in the formula (I) with an R-C≡CH, wherein R is as defined in the formula (I) above, in the presence of a copper catalyst to form a compound of the formula (II),
wherein R5 is R' and A, R3, R4, R' and Rp are as defined above.
In the step (i) of those methods for preparing the present compound of formula (I), the starting materials are commercially available or can be easily prepared a compound commercially available according to any know method. For example, the starting compound of the formula:
Figure imgf000024_0001
( I I )
wherein,
A is CH2-hydroxy; and
the other variable groups are as defined in the formula (I), can be prepared by performing following sub- steps:
(a) deglycosylation of tylosin under acidic condition, for example in the presence of HC1 aq.;
(b) reducing aldehyde group at 20-position in the presence of a reducing agent, such as NaBH i; and
(c) optionally converting the remaining functional groups to desired substituents according to any conventional process.
Figure imgf000025_0001
Figure imgf000025_0002
To enhance the reactivity of the 20- or 23-hydroxyl functional group, the starting compounds of formula (II) may, if desired, be halogenized, for example with a halogenating agent such as h or CCLt in the presence of PPI13 in a solvent such as pyridine and/or dichloromethyl at -27 to 40°C, preferably 0°C to rt, so that a compound of formula (II) wherein A is CH2-halo or R5 is halogen is formed.
By using a compound of formula (II) wherein either A is CH2-R' or R5 is R, which compound may be obtained from any of the preparing methods described above as a starting material, 20,23 -bistriazole tylosin derivative, that is a compound of the formula (I) wherein A is CH2-R' and R5 is R' may be prepared by carrying out the other preparing method as described above.
In a detailed example for formula (I), the azidation of step (i) in the preparing methods above can be carried out by reacting azide such as diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) with the starting material in the presence of solvent such as THF or DMSO at -27 to 100°C, preferably at 0 to 80°C. The reaction of step (ii) and (iv) in the preparing methods for formula (I) and (lib) above can be carried out in a solvent for example water, tert-butyl alcohol, methanol or acetonitrile or combination thereof, preferably in acetonitrile, preferably in the presence of tris[(l-benzyl-lH-l,2,3-triazol-4- yl)methyl] amine (TBTA), in the presence of a copper catalysis for example CuSO r5H20, CuOTf- CeH6, [Cu(NCCH3)4] [PF6] or Cul, preferably Cul at 0 to 100°C, preferably 10 to 40°C, more preferably rt.
Still further example for a method for preparing a compound of the formula (I):
Figure imgf000026_0001
CD
wherein Rl and R2 taken together are =N-O-C0-C3-alkyl-R' and A, R3, R4, R5, R' and Rp are as defined above;
which method comprises following steps:
(i) reacting a compound of the formula (II):
Figure imgf000026_0002
( I I ) wherein,
the variable groups are as defined in the formula (I), but A is not -CHO, with a CH≡C-(CH2)n-0- NH2-FIC1 wherein n is an integer from 1 to 3 to form a compound of the formula (III):
Figure imgf000027_0001
( I I I )
wherein n is an integer from 1 to 3 and A, R3, R4, R5 and Rp are as defined in formula (I), provided that A is not -CHO; and
(ii) reacting the compound of the formula (III) resulting from step (i) or (ii) with an R-N3, wherein R is as defined in formula (I) above, in the presence of a copper catalyst to form a compound of the formula (I):
Figure imgf000027_0002
wherein Rl and R2 taken together are =N-O-C0-C3-alkyl-R' and A, R3, R4, R5, R' and Rp are as defined above.
The starting compound of the formula (II):
Figure imgf000028_0001
( I I )
wherein,
the variable groups are as defined in the formula (I), but A is not -CHO can be readily available or prepared according to any conventional process known to the skilled person.
In a detailed embodiment, the introduction of an acetylene moiety of step (i) can be carried out by reacting a CH≡C-(CH2)n-0-NH2-HCl (wherein n is as defined above) with the starting material in a solvent such as pyridine or methanol or combination thereof, preferably in the combination of pyridine and methanol, at 0 to 80°C, preferably rt to 65°C. If desired, an oxo or hydroxyl group which is desired not to participate in the introduction of an acetylene moiety can be protected by any conventional process.
In a detailed example, the reaction of step (ii) and (iv) for formula (I) and (lib) can be carried out in solvent, for example water, tert-butyl alcohol, methanol or acetonitrile or combination thereof, preferably in acetonitrile, preferably in the presence of tris[(l-benzyl-lH-l,2,3-triazol-4- yl)methyl] amine (TBTA), in the presence of copper catalyst, for example CuSO r5H20, CuOTf-CeH6, [Cu(NCCH3)4][PF6] or Cul, preferably Cul at 0 to 100°C, preferably 10 to 40°C, more preferably rt.
The compounds represented by R-N3 and R-C^CH are commercially available or can be easily prepared by any conventional procedure known to a skilled person.
The process steps to synthesize the compounds of the invention can be carried out under reaction conditions that are known per se, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, including, for example, solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g., in the H+ form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, for example in a temperature range of from about -100 °C to about 190°C, including, for example, from approximately -80°C to approximately 150°C, for example at from -80 to -60°C, at room temperature, at from -20 to 40°C or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen atmosphere.
The solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofurane or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N- methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride, cyclic, linear or branched hydrocarbons, such as cyclohexane, hexane or isopentane, or mixtures of those solvents, for example aqueous solutions, unless otherwise indicated in the description of the processes. Such solvent mixtures may also be used in working up, for example by chromatography or partitioning. Within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention is designated a "protecting group," unless the context indicates otherwise. The protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as e.g., Science of Synthesis: Houben-Weyl Methods of Molecular Transformation. Georg Thieme Verlag, Stuttgart, Germany. 2005. 41627 pp. (URL: http://www.science- of-synthesis.com (Electronic Version, 48 Volumes)); J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in "Methoden der organischen Chemie" (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jeschkeit, "Aminosauren, Peptide, Proteine" (Amino acids, Peptides, Proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of Carbohydrates: Monosaccharides and Derivatives), Georg Thieme Verlag, Stuttgart 1974. A characteristic of protecting groups is that they can be removed readily (i.e., without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g., by enzymatic cleavage).
Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known per se. For example, salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g., the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used. Acid addition salts of compounds of the present invention are obtained in customary manner, e.g., by treating the compounds with an acid or a suitable anion exchange reagent. Internal salts of compounds of the present invention containing acid and basic salt- forming groups, e.g., a free carboxy group and a free amino group, may be formed, e.g., by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g., with weak bases, or by treatment with ion exchangers.
Intermediates and final products can be worked up and/or purified according to standard methods, e.g., using chromatographic methods, distribution methods, (re-) crystallization, and the like. The compounds, including their salts, may also be obtained in the form of solvates, in particular hydrates. In the context of the invention, solvates refer to those forms of the compounds according to the invention which, in the solid or liquid state, form a complex by coordination with solvent molecules. Hydrates are a specific form of the solvates in which the coordination is with water. Crystals of the present compounds may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
The invention relates also to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
This invention also encompasses pharmaceutical or veterinary compositions containing, and methods of treating bacterial infections through administering, pharmaceutically acceptable prodrugs of the compounds of the invention. For example, compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently bound through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10.
Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities. The compounds of the present invention have valuable pharmacological properties and thus they can be used for the treatment of diseases. In one embodiment, the compound of the present invention may be used for the treatment or prevention of bacterial infections or disorders associated with bacterial infections in animals, for example mammals, fish or birds. The term "animal", "patient" or "subject" as used herein is used interchangeably. The term animal typically includes, but is not limited to animals suffering from, at risk of suffering from, or potentially capable of suffering from a bacterial infection, for example humans, cattle, horses, chickens, pigs, sheep, goats, dogs, apes, cats, mice, rabbits, rats, etc.; especially farm animals such as cattle, pigs and poultry. As used herein, the term "bacterial infection(s)" includes, but is not limited to, bacterial infections that occur in mammals, fish and birds as well as disorders related to bacterial infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention. The compounds of the present invention are useful for treating infections caused by bacteria such as:
Staphylococcus spp, Streptococcus spp, Enterococcus spp, Neisseria spp, Moraxella spp, Corynebacterium spp, Lactobacillus spp, Bacillus spp, Listeria spp, Erysipelothrix spp, Arcanobacterium spp, Vibrio spp Aeromonas spp, Escherichia spp, Klebsiella spp, Proteus spp, Salmonella spp, Shigella spp, Morganella spp, Citrobacter spp, Enterobacter spp, Serratia spp, Erwinia spp, Yersinia spp, Pseudomonas spp, Alcaligenes spp, Burkholderia spp, Phyllobacterium spp, Acinetobacter spp, Stenotrophomonas spp, Haemophilus spp, Actinobacillus spp, Bordetella spp, Pasteurella spp, Brucella spp, Campylobacter spp, Capnytophaga spp, Francisella spp, Helicobacter spp, Legionella spp, Mycoplasma spp, Ureaplasma spp, Bartonella spp, Chlamydia spp, Coxiella spp, Ehrlichia spp, Rickettsia spp, Borrelia spp, Leptospira spp, Treponema spp, Brachyspira spp, Veillonella spp, Peptostreptococcus spp, Peptococcus spp, Bacteroides spp, Porphyromonas spp, Prevotella spp, Fusobacterium spp, Clostridium spp, Actinomyces spp, Propionibacterium spp, Eubacterium spp, Lactobacillus spp, Bifidobacterium spp. More specifically the present compounds can be used in the treatment or prevention of bacterial infections caused by gram-positive bacteria such as staphylococcal, streptococcal, Lactobacillus acidophilus, Corynebacterium diphtheriae, Propionibacterium acnes, Actinomyces bovis, Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus or Clostridium or gram-negative bacteria such as Pasteurella, Mannheimia or Mycoplasma infections in animals.
Such bacterial infections and disorders related to such infections include, but are not limited to, the following: acne, rosacea, skin infection, pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Peptostreptococcus spp. or Pseudomonas spp.; pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by Staphylococcus aureus, coagulase-positive staphylococci (i.e., S. epidermidis, S. hemolyticus, etc.), S. pyogenes, S. agalactiae, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, Corynebacterium spp., Clostridium spp., or Bartonella henselae; uncomplicated acute urinary tract infections related to infection by S. saprophyticus or Enterococcus spp.; urethritis and cervicitis; sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Nesseria gonorrheae; toxin diseases related to infection by S. aureus (food poisoning and Toxic shock syndrome), or Groups A, S. and C streptococci; ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by C. trachomatis, N. gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare; gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp., odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; Skin infection by S. aureus, Propionibacterium acne; atherosclerosis related to infection by Helicobacter pylori or Chlamydia pneumoniae; or the like.
Further bacterial infections and disorders related to such infections that may be treated or prevented in animals include, but are not limited to, the following: bovine respiratory disease related to infection by P. haemolytica., P. multocida, Mycoplasma bovis, or Bordetella spp.; cow enteric disease related to infection by E. coli or protozoa (i.e., coccidia, Cryptosporidia, etc.), dairy cow mastitis related to infection by S. aureus, S. uberis, S. agalactiae, S. dysgalactiae, Klebsiella spp., Corynebacterium, or Enterococcus spp.; swine respiratory disease related to infection by A. pleuropneumoniae., P. multocida, or Mycoplasma spp.; swine enteric disease related to infection by E. coli, Lawsonia intracellularis, Salmonella spp., or Serpulina hyodyisinteriae; cow footrot related to infection by Fusobacterium spp.; cow metritis related to infection by E. coli; cow hairy warts related to infection by Fusobacterium necrophorum or Bacteroides nodosus; cow pink-eye related to infection by Moraxella bovis, cow premature abortion related to infection by protozoa (i.e., neosporium); urinary tract infection in dogs and cats related to infection by E. coli; skin and soft tissue infections in dogs and cats related to infection by S. epidermidis, S. intermedius, coagulase neg. Staphylococcus or P. multocida; dental or mouth infections in dogs and goats related to infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium spp., Peptostreptococcus spp., Porphfyromonas spp., Campylobacter spp., Actinomyces spp., Erysipelothrix spp., Rhodococcus spp., Trypanosoma spp., Plasmodium spp., Babesia spp., Toxoplasma spp., Pneumocystis spp., Leishmania spp., Trichomonas spp. or Prevotella spp. Other bacterial infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J. P. Sanford at al., "The Sanford Guide To Antimicrobial Therapy," 26th Edition, (Antimicrobial Therapy, Inc., 1996). The compounds of the present invention is especially effective to respiratory diseases such as pasteurellosis caused by Gram negative bacillus such as Pasteurella or Mannheimia in farm animals such as cows.
Still further bacterial infections and disorders related to such infections that may be treated or prevented in animals especially by compounds of formula (Ila) as mentioned before include, but are not limited to, mastitis in all non-human milk-producing mammals, such as cattle, camel, buffalo, goat or sheep, and which may be associated with several pathogens including E. coli, Klebsiella spp., Enterobacter spp., Salmonella spp., Citrobacter spp., Serratia spp., Shigella spp., Edwardsiella spp., Hafnia spp., Morganella spp., Providencia spp., Yersinia spp., Staphylococcus aureus, Staphylococcus spp., Pseudomonas spp., Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus spp., Enterococci, Corynebacterium spp., Arcanobacterium spp., Actinomyces spp., Mycobacterium spp., Prototheca spp., Mycoplasma spp., and Erwinia spp., among others and in addition to the above mentioned pathogens related to mastitis. Of the mentioned non-human milk-producing mammals, ruminants that are used for milk production for human consumption, such as cattle, buffalo, sheep, and goat, are especially important.
Accordingly, in a certain embodiment, the present invention provides a pharmaceutical or veterinary composition comprising any of the compounds of the present invention. The composition may comprise therapeutically effective amount of the compound of the present invention, and if desired one or more pharmaceutically acceptable excipients or carriers.
The language "therapeutically effective amount" of the compound is that amount necessary or sufficient to treat or prevent a bacterial infection, e.g. prevent the various morphological and somatic symptoms of a bacterial infection, and/or a disease or condition described herein. In an example, an effective amount of the compound of the invention is the amount sufficient to treat a bacterial infection in a subject. The effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular compound of the invention. For example, the choice of the compound of the invention can affect what constitutes an "effective amount." One of ordinary skill in the art would be able to study the factors contained herein and make the determination regarding the effective amount of the compounds of the invention without undue experimentation.
The regimen of administration can affect what constitutes an effective amount. The compound of the invention can be administered to the subject either prior to or after the onset of a bacterial infection. Further, several divided dosages, as well as staggered dosages, can be administered daily or sequentially, or the dose can be continuously infused, or can be a bolus injection. Further, the dosages of the compound(s) of the invention can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation. Compounds of the invention may be used in the treatment of states, disorders or diseases as described herein, or for the manufacture of pharmaceutical or veterinary compositions for use in the treatment of these diseases. Methods of use of compounds of the present invention in the treatment of these diseases, or pharmaceutical or veterinary preparations comprising compounds of the present invention for the treatment of these diseases are also included in embodiments of the present invention.
The language "pharmaceutical or veterinary composition" includes preparations suitable for administration to mammals, e.g., farm animals such as cows. When the compounds of the present invention are administered as pharmaceuticals to mammals, e.g., cows, they can be given per se or as a pharmaceutical or veterinary composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier. The phrase "pharmaceutically acceptable carrier" is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals. The carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
Formulations of the present invention include those known in the art. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Methods of preparing these formulations or compositions are also known in the art.
The term "treat," "treated," "treating" or "treatment" includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated. In certain embodiments, the treatment comprises the induction of a bacterial infection, followed by the activation of the compound of the invention, which would in turn diminish or alleviate at least one symptom associated or caused by the bacterial infection being treated. For example, treatment can be diminishment of one or several symptoms of a disorder or complete eradication of a disorder.
Especially treatment of mastitis is curing or ameliorating an animal that has contracted mastitis, i.e. reducing at least one symptom of mastitis. Mastitis refers to inflammation of the mammary gland. Physical, chemical and usually bacteriological changes in the milk and pathological changes in the glandular tissue characterize it. The glandular changes often result in a number of symptomatic conditions such as, discoloration of the milk, the presence of clots and the presence of large numbers of leukocytes. Clinically, mastitis is seen as swelling, heat, pain and induration in the mammary gland often resulting in deformation of the udder. An inflamed udder can be visibly seen or determined through palpation of the udder. In many cases the diagnosis of subclinical infections has come to depend largely on indirect tests which depend on the leukocyte content of the milk (flakes, clots, or serous milk), at least 1 bacterium is detected in at least 100 μL· of milk from the udder, elevated somatic cell count (SCC) usually higher than 300,000 cells/mL and/or the electrical conductivity of the milk is increased from normal. Prevention of mastitis means preventing the occurrence of the infection. Prevention also includes treatment of cows that do not exhibit any signs of mastitis but are in the presence of other cows that do have at least one sign of mastitis to minimize or prevent the transmission or potential transmission of mastitis from one cow to another.
These compounds may be administered to humans and other animals for therapy by any suitable route of administration.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical or veterinary compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels of the active ingredients in the pharmaceutical or veterinary compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical or veterinary composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical or veterinary composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 1.0 to about 100 mg per kg per day. An effective amount is that amount treats a bacterial infection.
If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical or veterinary composition.
The antibacterial activity by the compounds of the present invention may be measured using a number of assays available in the art. An example of such an assay is the standard minimum inhibitory concentration (MIC) test conducted according to CSLI guidelines or paper disc test conducted according to Examples below.
Further disclosed are embodiments of compounds represented by the formula (I):
Figure imgf000040_0001
or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof;
wherein, A is selected from the group consisting of:
(1) -CHO or a protected aldehyde;
(2) CH2-X, wherein X is selected from the group consisting of:
a. hydroxy or protected hydroxy;
b. halogen; and
c. -N3
(3) -CN;
(4) -CH=N-NR7R8, wherein R7 and R8 are each independently selected from hydrogen, Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic or R7 and R8 taken with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain a hetero function selected from the group consisting of -0-, -NH-, -N(Cl-C6-alkyl)-, -N(aryl) -, -N (heteroaryl)-, -S-, -S(O)- and-S(0)2-;
(5) -CH=N-OR7, wherein R7 is as previously defined;
(6) C3-C14-cycloalkyl;
(7) substituted C3-C14-cycloalkyl;
(8) aryl;
(9) substituted aryl;
(10) heterocyclic;
(11) substituted heterocyclic;
(12) CH2-R';and
(13) -CH2-NR7R8, where R7 and R8 are as previously defined;
Rl and R2 are each independently selected from the group consisting of:
(1) hydrogen;
(2) hydroxy;
(3) protected hydroxy;
(4) -OC(0)-Cl-C12-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined;
(5) -0-R7, where R7 is as previously defined;
(6) halogen;
(7) -NR7R8, where R7 and R8 are as previously defined;
(8) Rl and R2 taken together are oxo; and (9) Rl and R2 taken together are =N-O-C0-C3-alkyl-R';
R3 is selected from the group consisting of:
(1) hydrogen;
(2) a hydroxy protecting group;
(3) -C(0)-Cl-C12-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined;
(4) Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined;
(5) C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined; and
(6) C2-C6-alkynyl, optionally substituted with one or more substitutents selected fron the group consisting of halogen, aryl, substituted aryl, heterocyclic, substituted heterocyclic, -0-R7 and -NR7R8 where R7 and R8 are as previously defined;
R4 is -M-Y, where M is:
(1) absent,
(2) -C(O)-,
(3) -C(0)N(R7)-, where R7 is as previously defined,
(4) -Cl-C6-alkyl-N(R7) -, where R7 is as previously defined,
(5) -C2-C6-allcenyl-N(R7) -, where R7 is as previously defined, or
(6) -C2-C6-alkynyl-N(R7) -, where R7 is as previously defined;
and where Y is:
(1) hydrogen,
(2) hydroxy protecting group,
(3) Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined,
(4) C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted hetreocyclic, -OR7 where R7 is as previously defined,
(5) C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined,
(6) aryl,
(7) substituted aryl,
(8) heterocyclic, or
(9) substituted heterocyclic;
R5 is selected from the group consisting of:
(1) hydrogen;
(2) hydroxy;
(3) protected hydroxy;
(4) halogen;
(5) -0-R7, where R7 is as previously defined;
(6) -N3 or R';
Rp is hydrogen or a hydroxy protecting group;
and each R' is independently [l,4]-epi-[l ,2,3]-triazoro-R; and where each R is independently selected from the group consisting of:
(1) Cl-C9-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined;
(2) C2-C9-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined;
(3) C2-C9-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, -OR7 where R7 is as previously defined;
(4) C3-C14-cycloalkyl;
(5) substituted C3-C14-cycloalkyl;
(6) aryl;
(7) substituted aryl;
(8) heterocyclic;
(9) substituted heterocyclic; and
(10) -COOR7, where R7 is as previously defined;
provided that at least one of A, Rl and R2 and R5 comprise R'.
Furthermore, compounds of said formula (I) are disclosed, wherein;
A is selected from halogen, CH2-N3, hydroxy, CHO, hydroxyCi-6alkyl, haloCi-6alkyl, methyl(3,5-di(Cl- C3-alkyl)-piperidino), CH2-R, and -CH2-NR7R8;
Rl and R2 taken together are oxo or =N-O-C0-C3-alkyl-R';
R3 is H;
R4 is H;
R5 is selected from hydroxy, N3, halogen, 6-deoxy-2,3-di-0-methyl-b-d-allo-hexapyranosyloxy and R'; and
R' is as defined above;
provided that at least one of A, Rl and R2 and R5 comprises R';
or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof.
Furthermore, compounds of said formula (I) are disclosed, wherein;
A is CH2-R'or -CH2-NR7R8; Rl and R2 taken together are oxo;
R3 is H;
R4 is H; and
R5 is 6-deoxy-2,3-di-0-methyl-b-d-allo-hexapyranosyloxy.
Furthermore, compounds of said formula (I) are disclosed, wherein;
A is CHO or methyl(3,5-dimethylpiperidino)or -CH2NR7R8;
Rl and R2 taken together are oxo;
R3 is H;
R4 is H; and
R5 is R'.
Furthermore, compounds of said formula (I) are disclosed, wherein;
Figure imgf000045_0001
Rl and R2 taken together are oxo;
R3 is H;
R4 is H; and
R5 is hydroxy. Furthermore, compounds of said formula (I) are disclosed, wherein;
A is CHO, methyl(3,5-dimethylpiperidino), or -CH2-NR7R8;
Rl and R2 taken together are =N-O-C0-C3-alkyl-R'; and
R3 is H;
R4 is H; and
R5 is 6-deoxy-2,3-di-0-methyl-b-d-allo-hexapyranosyloxy.
In the mentioned disclosure of compounds according to formula (I), R is preferably selected from the group consisting of
Figure imgf000046_0001
Further disclosed is a method for preparing a compound of the formula (I):
Figure imgf000046_0002
wherein A is CH2-R' and Rl, R2, R3, R4, R5, R' and Rp are as defined above; which method comprises following steps:
(i) reacting a compound of the formula (II):
Figure imgf000047_0001
( I I )
wherein,
A is CH2-hydroxy; and
the other variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein A is CH2-N3 and the other variable groups are as defined in the formula (I); and
(ii) reacting the resulting compound of the formula (II) wherein A is CH2-N3 and the other variable groups are as defined in the formula (I) with an R-C≡CH, wherein R is as defined in the formula (I) above, in the presence of a copper catalyst to form a compound of the formula (II),
wherein A is CH2-R' and R3, R4, R5, R' and Rp are as defined above.
Furthermore, a method for preparing a compound of the formula (I) is disclosed:
Figure imgf000047_0002
wherein R5 is R' and A, Rl, R2, R3, R4, R' and Rp are as defined above;
which method comprises following steps:
(i) reacting a compound of the formula (II):
Figure imgf000048_0001
( I I )
wherein,
R5 is hydroxy; and
the other variable groups are as defined in the formula (I), with an azide selected from diphenylphosphoryl azide (DPPA) or sodium azide (NaNs) to form a compound of said formula (II) wherein R5 is -N3 and the other variable groups are as defined in the formula (I); and
(ii) reacting the resulting compound of the formula (II) wherein R5 is -N3 and the other variable groups are as defined in the formula (I) with an R-C≡CH, wherein R is as defined in the formula (I) above, in the presence of a copper catalyst to form a compound of the formula (II),
wherein R5 is R' and A, R3, R4, R and Rp are as defined above.
Furthermore, a method for preparing a compound of the formula (I) is disclosed:
Figure imgf000048_0002
wherein Rl and R2 taken together are =N-O-C0-C3-alkyl-R' and A, R3, R4, R5, R' and Rp are as defined above;
which method comprises following steps:
(i) reacting a compound of the formula (II):
Figure imgf000049_0001
( I I )
wherein,
the variable groups are as defined in the formula (I), but A is not -CHO, with a CH≡C-(CH2)n-0- NH2-HC1 wherein n is an integer from 1 to 3 to form a compound of the formula (III):
Figure imgf000049_0002
( I I I) wherein n is an integer from 1 to 3 and A, R3, R4, R5 and Rp are as defined in formula (I), but A is not - CHO; and
(ii) reacting the compound of the formula (III) resulting from step (i) or (ii) with an R-N3, wherein R is as defined in formula (I) above, in the presence of a copper catalyst to form a compound of the formula (I):
Figure imgf000049_0003
CD wherein Rl and R2 taken together are =N-O-C0-C3-alkyl-R' and A, R3, R4, R5, R' and Rp are as defined above.
The invention is further illustrated by the following examples, which should not be construed as further limiting. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology and immunology, which are within the skill of the art.
EXAMPLES
All starting materials, building blocks, reagents, acids, bases, solvents, and catalysts, etc. utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21).
Analytical methods
Infrared (IR) absorption spectra were determined by using Horiba FT-210 spectrometer. ¾ NMR spectra were determined by using JEOL JNM-EX270 (270 MHz), VALIAN-400 NMR System (400 MHz). 13C NMR spectra were determined by using JEOL JNM-EX270 (67.5 MHz), VARIAN- 400 NMR system (100 MHz). Chemical shifts are indicated in δ (ppm) and coupling patterns are indicated by using following abbreviations: s : singlet; d : double; dd : double doublet; t : triplet; q : quartet; m : multiplet; br.d : broad doublet; br.dd : broad double doublet; br.dt : broad double triplet.
Low-resolution mass spectra (LC-MS) were determined by using JEOL JMS-DX300 Mass Spectrometer. High-resolution mass spectra (HRMS) were deteremined by using JEOL JMS-700 V Mass Spectrometer.
A thin-layer chromatography (TLC) was performed by using silica gel 60 F254 (Merck) and compounds were detected by using UV irradiation (254nm) or color development of phosphomolybden.
Column chromatography was performed by flash chromatography on silica gel 60 (Art. 1.09385) (Mark).
Thirty % of ammonium purchased from Kanto Chemical Co. Ltd. was used as NH4OH Preparation of Compounds of Formula (I)
Preparation of 20-triazole-20-deoxodesmycosins
(1) Preparation of desmycosin (YT6)
Figure imgf000052_0001
Tylosin (20. Og, 21.8 mmol) was dissolved in 0.2N HCl aq. (340 mL) and then the mixture was stirred at 35°C for 2 hours. After confirming complete consumption of the starting material, the reaction mixture was neutralized by adding IN NaOH aq., extracted with CHCI3 and dried over Na2S04. The solvent was removed under reduced-pressure to obtain quantitative amount of desmycosin (YT6).
(2) Preparation of 20-dihydrodesmycosin (YT7)
Figure imgf000052_0002
To a solution of Desmycosin (16.8 g, 21.8 mmol) in z'-PrOH : H2O = 3 : 2 (300 mL) was added NaBFL (0.206 g, 5.45 mmol) and then the mixture was stirred at rt for 30 minutes. The reaction mixture was concentrated, neutralized by adding sat. NaHC03 aq., extracted with CHCI3 and dried over Na2S04. The solvent was removed under reduced pressure to obtain YT7 (Yield: 95%). (3) Preparation of 20-chloro-20-deoxodesmycosin (YT8)
Figure imgf000053_0001
To a solution of YT7 (16.9 g, 21.8 mmol) in CH2C12 : pyridine = 1 : 1 (330 mL) were added PPh3 (17.2 g, 65.4 mmol) and CCLt (3.2 g, 32.7 mmol) under N2 atmosphere and the mixture was stirred for 16 hours at rt. The reaction mixture was diluted with CHCI3, washed sequentially with sat. NaHCC aq., brine. The organic layer was dried over Na2S04 and then the solvent was removed under reduced pressure. The resulting products were purified by flash column chromatography to obtain YT8 (Yield: 83%).
Figure imgf000053_0002
To a solution of YT8 (12.4 g, 15.7 mmol) in DMSO (160 mL, 0.100 M) was added NaN3 (5.10 g, 78.3 mmol) and then the mixture was stirred for 20 hours at 80°C. The reaction mixture was diluted with AcOEt and water. The organic layer was separated, the aqueous layer was extracted with AcOEt and the combined organic layer was washed with water, brine, and then dried over Na2S04 and concentrated. The resulting products were purified by flash column chromatography to obtain YT11 (Yield: 90%). (5) Preparation of 20-triazole-20-deoxodesmycosins
Figure imgf000054_0001
To a solution of YT11 (0.24 g, 0.30 mmol) in CH3CN or MeOH (3.0 mL) were added copper catalyst (2.9 mg, 0.015 mmol), TBTA (1.6 mg, 3.0 μιηοΐ) or 2,6-lutidine (0.01 eq.) and acetylene compound wherein R is p-ethynyl (pentyloxy)benzene or phenyl (0.33 mmol) and the mixture was stirred at rt until the reaction was completed. After completion, the reaction mixture was diluted with CHCb, washed with 10% NH3 aq.. After removing copper catalyst, the filtrate was washed with brine. The organic layer was dried over Na2S04 and concentrated. The resulting products were purified by flash column chromatography to obtain the triazole compounds.
The results of the step (5) are shown in Table 1 below.
Table 1 Reaction times*
Solvents (0.1 R = / ethynyl
Entry Conditions R = Ph
M) (pentyloxy)benzene
Figure imgf000054_0002
Cu(CH3CN)4PF6 (0.05 eq.)
2 MeOH 2days 2days
TBTA (0.01 eq.), rt
Figure imgf000054_0003
Cul (0.05 eq.)
4 MeOH 50 min 120min
TBTA (0.01 eq.), rt
Figure imgf000054_0004
Time for consumption of the starting material. Under the conditions of Entry 4 or 5 above, with the following nineteen compounds:
Figure imgf000055_0001
yt12 yt13 yt14 yt16
Figure imgf000055_0002
yt17 yt18 yt19 yt20
Figure imgf000055_0003
yt21 yt22 yt23 yt24
Figure imgf000055_0004
yt25 yt26 yt27 yt28
Figure imgf000055_0005
yt29 yt30 yt32
as the acetylene compound, the step (5) above was repeated to obtain the 20-triazole-20- deoxodesmycosins, which are shown below.
20-(4-(pyridine-2-yl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT12)
Figure imgf000056_0001
Yield: 85%
20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT13)
Figure imgf000056_0002
Yield:98%
20-(4-(thiophene-3-yl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT14)
Figure imgf000057_0001
Yield:81%
-(4-(pyridine-3-yl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT16)
Figure imgf000057_0002
Yield: 82%
20-(4-(3-aminophenyl-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT17)
Figure imgf000058_0001
Yield:91%
20-(4-(3-aminophenyl-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT18)
Figure imgf000058_0002
Yield:67%
20-(4-(4-chlorobutyl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT19)
Figure imgf000059_0001
Yield:54%
20-(4-butyl-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT20)
Figure imgf000059_0002
Yield:83%
20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT21)
Figure imgf000060_0001
Yield:86%
20-(4-ethoxycarbonyl-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT22)
Figure imgf000060_0002
Yield:86%
20-(4-(phenanthrene-8-yl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT23)
Figure imgf000061_0001
Yield:93%
20-(4-(4-phenoxyphenyl)-lH-l 2,3-triazol-l-yl)-20-deoxodesmycosin (YT24)
Figure imgf000061_0002
Yield:85%
20-(4-(2,4,5-trimethylphenyl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT25)
Figure imgf000062_0001
Yield:73%
20-(4-(4-i-butylphenyl)-lH-l, T26)
Figure imgf000062_0002
Yield: 88%
20-(4-(4-pentyloxyphenyl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT27)
Figure imgf000063_0001
Yield:86%
20-(4-(l-methyl-lH-benzotriazole)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT28)
Figure imgf000063_0002
Yield:96%
20-(4-(4-dimethylaminophenyl)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT29)
Figure imgf000064_0001
Yield:89%
20-(4-(Ar-methy-methylamine)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT30)
Figure imgf000064_0002
Yield:80%
20-(4-(l-methy-l-hydroxyleth -lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT32)
Figure imgf000065_0001
Yield:92%
20-(4-(2-methy-propyl)-lH-l,2 3-triazol-l-yl)-20-deoxodesmycosin (YT33)
Figure imgf000065_0002
Yield:89%
20-(4-nonyl-lH-l,2,3-triazol-l- l)-20-deoxodesmycosin (YT34)
Figure imgf000065_0003
Yield:97% 20-(4-(3-quinoline)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT35)
Figure imgf000066_0001
Yield:93%
20-(4-(4-butanol)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT36)
Figure imgf000066_0002
Yield:97%
20-(4-(methanol)-lH-l,2,3-triazol-l-yl)-20-deoxodesmycosin (YT37)
Figure imgf000067_0001
Yield: 100%
Preparation of 23-triazole-23-deoxo-5-0-mycaminosyltylonolides
(1) Preparation of 5-O-mycaminosyltylonolide (YT106)
Figure imgf000067_0002
Tylosin (9.16 g, 10.0 mmol) was dissolved to 0.5 M TFA solution (300 mL) and then the mixture was stirred for 5 hours at 100°C. After confirming complete consumption of the starting material, the reaction mixture was neutralized by adding NaHC03 sat. aq., extracted with CHCI3 and dried over Na2S04. The solvent was removed under reduced-pressure. The resulting products were purified by flash column chromatography to obtain YT106 (Yield: 39%). (2) Preparation of 23-azido-23-deoxo-5-Q-mycaminosyltylonolide (YT107)
Figure imgf000068_0001
To a solution of PPI13 (787 mg, 3.0 mmol) and I2 (381 mg, 3.0 mmol) in pyridine (4.0 mL) was added YT106 (300 mg, 0.50 mmol) under N2 atmosphere and then stirred for 4 hours at rt. After confirming complete consumption of the starting material, the reaction mixture was diluted with CHCl 3 . The organic layer was washed with Na2S203 sat. aq. and dried over Na2SO i. The solvent was then removed under reduced pressure. The resulting products were purified by flash column chromatography to obtain 23-I-23-deoxo-5-0-mycaminosyltylonolide (Yield: 46%). To a solution of 23-I-23-deoxo-5-0-mycaminosyltylonolide (155 mg, 0.22 mmol) in DMSO (2.0 mL) was added NaNb (50 mg, 0.77 mmol) and then the mixture was stirred for 90 minutes at 60°C. After confirming complete consumption of the starting material by mass spectrometry, the reaction mixture was diluted with CHCl 3. The organic layer was washed with water and dried over Na2S04. The solvent was removed under reduced pressure. The resulting products were purified by flash column chromatography to obtain YT107 (Yield: 84%).
(3) Preparation of 23-triazole-23-deoxy-5-0- mycaminosyltylonolides
To a solution of YT107 (0.24 g, 0.30 mmol) in CH3CN or MeOH (3.0 mL) were added Cul (2.9 mg, 0.015 mmol), TBTA (1.6 mg, 3.0 μιηοΐ) and a suitable acetylene compound, and then the mixture was stirred at rt until the reaction was completed. After completion, the reaction mixture was diluted with CHCI3, and washed with 10% NH3 aq.. After removing Cul, the filtrate was washed with brine. The organic layer was dried over Na2S04 and concentrated. The resulting products were purified by flash column chromatography to obtain the following triazole compounds:
23-(4-phenyl-lH-l,2,3-triazol-l-yl)-23-Deoxy-5-0-mycaminosyltylonolide (YTlOl)
20
Figure imgf000069_0001
YT101
Yield: 64%
Rf : 0.5 (CHCls : MeOH : NH4OH = 8 : 1 : 0.008).
23-(4-butyl-lH-l,2,3-triazol-l-yl)-23-Deoxo-5-6>-mycaminosyltylonolide (ΥΊΊ02)
20
Figure imgf000069_0002
Yield: 77% 23-(4-(3-quinoline-3-yl)-lH-l,2,3-triazol-l-yl)-23-Deoxo-5-0-mycaminosyltylonolide (YT103)
Figure imgf000070_0001
Yield: 100%
23-(4-biphenyl-lH-l,2,3-triazol-l-yl)-23-Deoxy-5-0-mycaminosyltylonolide (YT104)
Figure imgf000070_0002
YT104
Yield: 100%
23-(4-(pyridine-3-yl)-lH-l,2,3-triazol-l-yl)-23-Deoxo-5-0-mycaminosyltylonolide (YT109)
20
Figure imgf000070_0003
Yield: 94% 23-(4-(methyl-lH-benzotriazolyl)-lH-l,2,3-triazol-l-yl)-23-deoxo-5-0-mycaminosyltylonolide (YT110)
20
Figure imgf000071_0001
Yield: 94%
Preparation of 20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxo-23-triazole-23-deoxy-5-O-mycaminosylt- ylonolides 1) Preparation of 20-(4-phenyl-lH-l,2,3-triazol-l-yl -20-deoxo-5-O-mycaminosyltylonolide (YTl 12)
Figure imgf000071_0002
YT13 (0.5 g, 0.56 mmol) was dissolved in HBr (3.0 niL) and then the mixture was stirred for 30 minutes at 50°C. After confirming complete consumption of the starting material, the reaction mixture was neutralized by adding NaHC03 sat. aq., extracted with CHCI3 and dried over Na2SO i. The solvent was removed under reduced pressure. The resulting products were purified by flash column chromatography to obtain YTl 12 (Yield: 39%). (2) Preparation of 20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxo-23-azido-23-deoxy-5-O-mycatninosylt- ylonolide (YT114)
Figure imgf000072_0001
To a solution of PPI13 (144 mg, 0.55 mmol) and h (70 mg, 0.55 mmol) in pyridine (1.0 mL) was added YT112 (80 mg, 0.11 mmol) under N2 atmosphere and then the mixture was stirred for 4 hours at rt. After confirming complete consumption of the starting material, the reaction mixture was diluted with CHCI3. The organic layer was washed with Na2S203 sat. aq. and dried over Na2SO i. The solvent was removed under reduced pressure. The resulting products were purified by flash column chromatography to obtain 20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxo-23-I-23-deoxy-5-O-mycaminosyltylonolide (Yield: 64%).
To a solution of 20-(4-phenyl-lH-l,2,3-triazol-l -yl)-20-deoxo-23-I-23-deoxy-5-O-mycaminosyltyl- onolide (57 mg, 0.068 mmol) in DMSO (0.6 mL) was added NaN3 (13 mg, 0.20 mmol) and then the mixture was stirred for 30 minutes at 60 °C. After confirming complete consumption of the starting material by LC Mass, the reaction mixture was diluted with CHCI3. The organic layer was washed with water and dried over Na2S04. The solvent was removed under reduced pressure. The resulting products were purified by flash column chromatography to obtain YT114 (Yield: 96%).
(3) Preparation of 20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxo-23-triazole-23-deoxy-5-O-mycamino- syltylonolides
To a solution of YT114 (0.24 g, 0.30 mmol) in CH3CN or MeOH (3.0 mL) were added Cul (2.9 mg, 0.015 mmol), TBTA (1.6 mg, 3.0 μιηοΐ) and a suitable acetylene compound, and then the mixture was stirred at rt until the reaction was completed. After completion, the reaction mixture was diluted with CHCI3, washed with 10% NH3 aq.. After removing Cul, the filtrate was washed with brine. The organic layer was dried over Na2S04 and concentrated. The resulting products were purified by flash column chromatography to obtain the following triazole compounds:
20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxo-23-(4-phenyl-lH-l,2,3-triazol-l-yl)-23-deoxy-5-6>- mycaminosyltylonolide (YT115)
Figure imgf000073_0001
Yield: 85%
20-(4-phenyl-lH-l,2,3-triazol-l-yl)-20-deoxo-23-(4-butyl-lH-l,2,3-triazol-l-yl) -23-deoxy-5-0- mycaminosyltylonolide (YT116)
Figure imgf000073_0002
Yield: 92% Preparation of Compounds of Formula (Ila)
General procedure for reductive amination from O-mycaminosyltylonolide (OMT)
Figure imgf000074_0001
To a solution of O-mycaminosyltylonolide (OMT) in 1 ,2-dichloroethane (0.1 M) at room temperature was added amines (1.5 to 2.0 equiv.), NaBH(OAc)3 (1.5 equiv.), and AcOH (3.0 equiv.). The reaction mixture was stirred at room temperature until OMT was consumed. After the reaction was quenched with sat. NH4CI aq., the resulting mixture was extracted with CHCI3 (3 times). The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude product was purified by silica gel chromatography (CHCl3/MeOH/NH4OH=l 00/1/0.1 to 10/1/0.1) to afford desired compounds.
YT615
Figure imgf000074_0002
According to the general procedure for reductive amination with OMT, OMT (200.0 mg, 0.335 mmol) with 2-azidoethylamine in 1.0 M solution of H2O (669.0 mL, 0.669 mmol) was converted to YT615 (124.3 mg, 56%) as a colorless solid.
HRMS (ESI) m/z :690.4041 [M+Na]+, calcd for C33H57N509Na: 690.4054. YT646
Figure imgf000075_0001
According to the general procedure for reductive amination with OMT, OMT (1.0 g, 1.67 mmol) with N-methylpropargyl amine (209.0 mL, 2.51 mmol) was converted to YT646 (1.01 g, 93%) as a colorless solid. HRMS (ESI) m/z :651.4202 [M+H]+, calcd for C35H59N2O9: 651.4221.
YT649
Figure imgf000075_0002
According to the general procedure for reductive amination with OMT, OMT (100 mg, 0.167 mmol) with N-(2-azidoethyl)benzylamine (32.6 iL, 0.251 mmol) was converted to YT649 (98.7 mg, 82%) as a colorless solid. HRMS (ESI) m/z :758.4700 [M+H]+, calcd for C40H64N5O9: 758.4704.
YT699
Figure imgf000076_0001
According to the general procedure for reductive animation with OMT, OMT (1.99 g, 3.33 mmol) with N-(2-azidoethyl)-4-iodobenzylamine (1.51 g, 5.00 mmol) was converted to YT699 (2.44 g, 83 %) as a colorless solid. HRMS (ESI) m/z :884.3669 [M+H]+, calcd for C40H63IN5O9: 884.3670.
YT711
Figure imgf000076_0002
According to the general procedure for reductive amination with OMT, OMT (1.63 g, 2.72 mmol) with N-benzylpropargyl amine (1.66 g, 4.08 mmol) was converted to YT711 (1.49 g, 75%) as a colorless solid. HRMS (ESI) m/z :727.4532 [M+H]+, calcd for C41H63N2O9: 727.4534. YT712
Figure imgf000077_0001
According to the general procedure for reductive animation with OMT, OMT (100.0 mg, 0.167 mmol) with N-propargyl amine (16.1 mL, 0.251 mmol) was converted to YT712 (50.4 mg, 47%) as a colorless solid. HRMS (ESI) m/z :637.4073 [M+H]+, calcd for C34H57N2O9: 637.4064.
Synthesis of YT616
Figure imgf000077_0002
To a solution of OMT (500.0 mg, 0.836 mmol) in pyridine (5 mL) was added AcOH (2.4 mL, 41.8 mmol). The reaction was stirred at room temperature for lh. After to the reaction mixture was added water, the solvent was evaporated with toluene. The residue was dissolved in CHCI3 (10 mL), the organic layer was washed with water (5 mL). The organic layer was dried over Na2S04 and concentrated in vacuo. The crude product was used next step without further purification. To a solution of the crude product in MeOH (6.2 mL) was added NaBLL (15.8 mg, 0.418 mmol). The reaction was stirred at room temperature for 30 min. After addition of water (3 mL), the mixture was extracted with EtOAc (10 mL, x3). The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude product was used next step without further purification. To a solution of the crude product in toluene (10 mL) was DPPA (215.0 mL, 1.00 mmol) and DBU (140.9 mL, 1.00 mmol). The reaction was stirred at 0 °C for 1 h 15 min. After addition of brine (3 mL), the mixture was extracted with EtOAc (10 mL, x3). The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude product was used next step without further purification. To a solution of the crude product in DMF (6.8 mL) was added NaNb (108.7 mg, 1.672 mmol). The reaction was stirred at 80 °C for 19 h. After the reaction was cooled to room temperature and diluted with EtOAc, the reaction mixture was washed with H2O. The organic layer was dried over Na2S04 and concentrated in vacuo. The crude product was used next step without further purification. To a solution of the crude product in MeOH (5.0 mL) was added a solution of 10 % K2CO3 in water (3.0 mL). The reaction was stirred at room temperature for 16 h. The reaction mixture was extracted with AcOEt (10 mL, x3). The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude product was purified by silica gel chromatography (CHCl3/MeOH/NH4OH=l 00/1/0.1 to 10/1/0.1) to afford YT616 (91.7 mg, 18% over 6 steps) as a colorless solid. HRMS (ESI) m/z :625.3803 [M+H]+, calcd for C31H53N4O9: 625.3813.
General procedure for triazole reaction.
Method A) To a solution of azide- or acetylene-tylosin analogues in MeOH (0.1 M) at room temperature was added acetylenes or azide building blocks (1.0-2.0 equiv.), tetrakis(acetonitrile)copper(I) hexafluorophosphate (Cu(MeCN)4PF6, 0.1-0.5 mol%), and tris[(l-benzyl-lH-l,2,3-triazol-4- yl)methyl] amine (TBTA, 0.1-0.5 mol%). The reaction mixture was stirred at room temperature until a starting material was consumed. After the reaction was added sat. NH4CI aq., the resulting mixture was extracted with CHCI3 (3 times). The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude product was purified by silica gel chromatography (CHCl3/MeOH/NH4OH=l 00/1/0.1 to 10/1/0.1) to afford desired compounds.
Method B) To a solution of azide- or acetylene-tylosin analogues in MeOH (0.1 M) at room temperature was added acetylenes or azide building blocks (1.0-2.0 equiv.), tetrakis(acetonitrile)copper(I) hexafluorophosphate (Cu(MeCN)4PF6, 0.1-0.5 mol%), and tris[(l-benzyl-lH-l,2,3-triazol-4- yl)methyl] amine (TBTA, 0.1-0.5 mol%). The reaction mixture was stirred at 70 °C for 15 to 30 min under microwave irradiation until a starting material was consumed. After the reaction was cooled to room temperature and added sat. NH4CI aq., the resulting mixture was extracted with CHCI3 (3 times). The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude product was purified by silica gel chromatography (CHCl3/MeOH/NH4OH=l 00/1/0.1 to 10/1/0.1) to afford desired compounds. Method C) To a solution of azide- or acetylene-tylosin analogues in i-BuOH/EhO (0.03 M) at room temperature was added acetylenes or azide building blocks (1.0-2.0 equiv.), CuS04 (0.1 mol%), and sodium ascorbate (0.5 equiv.). The reaction mixture was stirred at room temperature until a starting material was consumed. After the reaction was added sat. Rochelle salt aq., the resulting mixture was extracted with AcOEt (3 times). The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude product was purified by silica gel chromatography (CHCl3/MeOH/NH4OH=l 00/1/0.1 to 10/1/0.1) to afford desired compounds.
YT617
Figure imgf000079_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT615 (67.5 mg, O.lOlmmol) with ethynylbenzene (25.0 μΐ., 0.228 mmol) was converted to YT617 (41.8 mg, 53%) as a colorless solid. HRMS (ESI) m/z :770.4676 [M+H]+, calcd for C41H64N5O9: 770.4704. YT620
Figure imgf000080_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (47.0 mg, 0.0752 mmol) with 2-propyn-l -ol (9.0 μΐ,, 0.155 mmol) was converted to YT620 (30.5 mg, 61%) as a colorless solid. HRMS (ESI) m/z :703.3891 [M+Na]+, calcd for
Figure imgf000080_0002
703.3894.
YT625
Figure imgf000080_0003
According to the general procedure (method A) for synthesis of triazole analogues, YT615 (121.3 mg, 0.182 mmol) with 2-propyn-l -ol (21.0 μΐ,, 0.361 mmol) was converted to YT625 (62.9 mg, 48%) as a colorless solid. HRMS (ESI) m/z :724.4486 [M+H]+, calcd for C36H62N5O10: 724.4497.
Figure imgf000080_0004
According to the general procedure (method A) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with tetra-OAc-P-D-glucopyranosyl azide (86.0 mg, 0.230 mmol) was converted to YT647 (92 mg, 58%) as a colorless solid. HRMS (ESI) m/z : 1024.5336 [M+H]+, calcd for C49H78N5O18: 1024.5342. YT648
Figure imgf000081_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with tri-OAc-6-N3- -D-methylglucopyranoside (79.0 mg, 0.229 mmol) was converted to YT647 (51.8 mg, 50%) as a colorless solid. HRMS (ESI) m/z :996.5378 [M+H]+, calcd for C48H78N5O17: 996.5393.
YT650
Figure imgf000081_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT646 (1.0 g, 1.54 mmol) with 3-azidoquinoline (392.0 mg, 2.30 mmol) using method B) was converted to YT650 (1.21 g, 95%) as a colorless solid. [a]31 D -l 14.1 (c 1.0, CHCI3); ¾ NMR (500 MHz, CD3OD) δ (ppm) : 9.49 (d, J = 2.3 Hz, 1H), 8.90 (d, J = 2.3 Hz, 1H), 8.89 (s, 1H), 8.17 (d, J = 8.0 Hz, 1H), 8.13 (d, J = 8.6 Hz, 1H), 7.89 (app t, J= 8.0 Hz, 1H), 7.75 (app t, J= 7.7 Hz, 1H), 7.14 (d, J= 15.5 Hz, 1H), 6.47 (d, J= 15.5 Hz, 1H), 5.51 (d, J = 10.3 Hz, 1H), 4.51 (app t, J = 8.9 Hz, 1H), 4.23 (d, J = 8.0 Hz, 1H), 3.94 (d, J = 14.3 Hz, 1H), 3.85 (dd, J = 1.7, 9.7 Hz, 1H), 3.59 (d, J= 10.3 Hz, 1H), 3.52 (d, J = 13.8 Hz, 1H), 3.42 (dd, J = 4.0, 10.9 Hz, 1H), 3.35 (dd, J= 8.0, 10.9 Hz, 1H), 3.26-3.19 (complex m, 2H), 3.13 (app t, J= 9.5 Hz, 1H), 2.86 (m, 1H), 2.76 (m, 1H), 2.66 (m, 1H), 2.50 (s, 6H), 2.45-2.29 (complex m, 3H), 2.23 (s, 3H), 2.05 (d, J = 17.2 Hz, 1H), 1.88-1.73 (complex m, 3H), 1.80 (s, 3H), 1.72-1.63 (complex m, 2H), 1.59- 1.42 (complex m, 3H), 1.24 (d, J = 5.7 Hz, 3H), 1.21 (d, J = 6.9 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H), 0.84 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.5, 174.3, 149.6, 148.4, 146.8, 145.2, 144.9, 136.5, 132.2, 132.0, 129.9, 129.7, 129.4, 129.1, 128.9, 124.3, 119.4, 105.7, 80.6, 76.1, 74.3, 72.6, 71.73, 71.66, 68.4, 62.4, 56.0 52.7, 48.3, 46.7, 43.1, 42.7, 42.2 (2C), 40.3, 34.9, 34.1, 26.2, 26.1, 18.3, 17.9, 13.2, 9.9, 9.7; HRMS (ESI) m/z :821.4812 [M+H]+, calcd for C44H65N6O9: 821.4813.
YT651
Figure imgf000082_0001
According to the general procedure (method C) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with azidomethyl benzene (30.8 mg, 0.230 mmol) was converted to YT651 (86.1 mg, 71%) as a pale yellow solid. HRMS (ESI) m/z :784.4851 [M+H]+, calcd for C42H66N5O9: 784.4861. YT652
Figure imgf000083_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with 2-acetamido-4,6-0-benzylidene-2-deoxy-P -D-glucopyranosylazide (62.0 mg, 0.185 mmol) was converted to YT652 (117.8 mg, 78%) as a pale yellow solid. HRMS (ESI) m/z :985.5477 [M+H]+, calcd for C50H77N6O14: 985.5498.
YT653
Figure imgf000083_0002
According to the general procedure (method C) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with N-(2-azidoethyl)-benzylamine (40.6 mg, 0.230 mmol) was converted to YT653 (103.9 mg, 82%) as a pale yellow solid. HRMS (ESI) m/z :827.5277 [M+H]+, calcd for C44H71N6O9: 827.5283. YT654
Figure imgf000084_0001
According to the general procedure (method C) for synthesis of triazole analogues, YT649 (100.0 mg, 0.132 mmol) with ethynylbenzene (21.7 μΐ,, 0.198 mmol) was converted to YT654 (106.6 mg, 94%) as a pale yellow solid. HRMS (ESI) m/z :860.5157 [M+H]+, calcd for C48H70N5O9: 860.5174.
YT657
Figure imgf000084_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT649 (100.0 mg, 0.132 mmol) with w-ethynylaniline (30.0 μΕ, 0.264 mmol) was converted to YT657 (71.4 mg, 62%) as a pale yellow solid. HRMS (ESI) m/z :875.5262 [M+H]+, calcd for C48H7iN609: 875.5283. YT664
Figure imgf000085_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT649 (100.0 mg, 0.132 mmol) with 3-ethynylpyridine (27.0 mg, 0.262 mmol) was converted to YT664 (46.9 mg, 41%) as a pale yellow solid. HRMS (ESI) m/z :861.5110 [M+Na]+, calcd for C45H7oN609Na: 861.5102.
YT665
Figure imgf000085_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT649 (100.0 mg 0.132 mmol) with l-ethynyl-4-pentylbenzene (51.0 μΕ, 0.263 mmol) was converted to YT665 (46.6 mg 38%) as a pale yellow solid. HRMS (ESI) m/z :952.5767 [M+Na]+, calcd for Css^NsC^Na: 952.5776. YT666
Figure imgf000086_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT649 (100.0 mg, 0.132 mmol) with cyclopropylacetylene (22.0 L, 0.260 mmol) was converted to YT666 (30.4 mg, 28%) as a pale yellow solid.HRMS (ESI) m/z : 846.4986 [M+Na]+, calcd for C45H69N509Na: 846.4993.
YT674
Figure imgf000086_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT649 (100 mg, 0.132 mmol) with 3-ethynylthiophene (19.5μΕ, 0.198 mmol) was converted to YT674 (49.2 mg, 43%) as a pale yellow solid. HRMS (ESI) m/z :866.4738 [M+H]+, calcd for C46H68N5O9S: 866.4738. YT680
Figure imgf000087_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT649 (100 mg, 0.132 mmol) with 4-ethynylbiphenyl (35.3 mg, 0.198 mmol) was converted to YT680 (48.2 mg, 39%) as a pale yellow solid. HRMS (ESI) m/z :936.5478 [M+H]+, calcd for C54H74N5O9: 936.5487.
YT687
Figure imgf000087_0002
According to the general procedure (method C) for synthesis of triazole analogues, YT649 (100 mg, 0.132 mmol) with l-ethynyl-4-phenoxybenzene (35.9 μΕ, 0.198 mmol) was converted to YT687 (57.6 mg, 46%) as a pale yellow solid. HRMS (ESI) m/z :952.5444 [M+H]+, calcd for C54H74N5O10: 952.5434. YT696
Figure imgf000088_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT649 (100 mg, 0.132 mmol) with / i-butylphenylacetylene (47.0 μΐ^, 0.264 mmol) was converted to YT696 (55.7 mg, 46%) as a pale yellow solid. HRMS (ESI) m/z :916.5784 [M+H]+, calcd for C52H78N5O9: 916.5800.
YT700
Figure imgf000088_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT699 (100.0 mg, 0.133 mmol) with ethynyl benzene (18.7 μΐ,, 0.170 mmol) was converted to YT700 (92.7 mg, 83%) as a pale yellow solid. HRMS (ESI) m/z :986.4143 [M+H]+, calcd for C48H69IN5O9: 986.4140. YT701
Figure imgf000089_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT699 (100.0 mg, 0.133 mmol) with 4-ethynyl biphenyl (30.3 mg, 0.170 mmol) was converted to YT701 (102.9 mg, 86%) as a pale yellow solid. HRMS (ESI) m/z : 1062.4446 [M+H]+, calcd for C54H73IN5O9: 1062.4453.
YT705
Figure imgf000089_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT699 (100.0 mg, 0.133 mmol) with 3-ethynylthiophene (17.4 μΕ, 0.170 mmol) was converted to YT705 (100.5 mg, 71%) as a pale yellow solid. HRMS (ESI) m/z :992.3687 [M+H]+, calcd for C46H67IN5O9S : 992.3704. YT706
Figure imgf000090_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT699 (100.0 mg, 0.133 mmol) with l-ethynyl-4-phenoxybenzene (31.8 μΐ^, 0.170 mmol) was converted to YT706 (97.2 mg, 68%) as a pale yellow solid. HRMS (ESI) m/z : 1078.4388 [M+H]+, calcd for C54H73IN5O10: 1078.4402.
YT707
Figure imgf000090_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT699 (100.0 mg, 0.133 mmol) with l-ethynyl-2,4,5-trimethyl benzene (25.3 mg, 0.170 mmol) was converted to YT707 (99.8 mg, 73%) as a pale yellow solid. HRMS (ESI) m/z : 1028.4588 [M+H]+, calcd for C51H75IN5O9: 1028.4609. YT708
HRMS (ESI) m/z :694.4379 [M+H]+, calcd for C35H60N5O9: 694.4391.
YT709
Figure imgf000091_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT711 (100.0 mg, 0.138 mmol) with 3-azidoquinoline (30.4 mg, 0.179 mmol) was converted to YT709 (113.9 mg, 92%) as a colorless solid. [a]31 D -124.7 (c 1.0, CHCI3); ¾ NMR (500 MHz, CD3OD) δ (ppm) : 9.49 (d, J= 2.3 Hz, 1H), 8.95 (s, 1H), 8.89 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 8.12 (d, J = 8.6 Hz, 1H), 7.88 (app t, J = 8.0 Hz, 1H), 7.74 (app t, J = 8.0 Hz, 1H), 7.44 (d, J = 7.5 Hz, 2H), 7.38 (app t, J = 7.5 Hz, 2H), 7.27 (t, J = 7.5 Hz, 1H), 7.10 (d, J = 15.5 Hz, 1H), 6.48 (d, J = 15.5 Hz, 1H), 5.72 (d, J = 10.9 Hz, 1H), 4.78 (m, 1H), 4.01-3.67 (complex m, 3H), 3.94 (d, J =7.5 Hz, 1H), 3.57-3.43 (complex m, 4H), 3.26 (dd, J = 10.3, 8.0 Hz, 1H), 3.20 (d, J = 12.6 Hz, 1H), 3.02 (t, 9.7 Hz, 1H), 2.97 (m, 1H), 2.87-2.78 (complex m, 2H), 2.67 (m, 1H), 2.54 (dd, J = 17.2, 10.3 Hz, 1H), 2.45 (s, 6H), 2.22-2.15 (complex m, 2H), 2.08 (d, J = 17.2 Hz, 1H), 1.94 (m, 1H), 1.84 (s, 3H), 1.83-1.46 (complex m, 7H), 1.21 (d, J = 6.9 Hz, 3H), 1.04 (d, J= 6.3 Hz, 3H), 1.03 (d, J= 6.9 Hz, 3H), 0.91 (t, J= 7.5 Hz, 3H). 13C NMR (125 MHz, CD3 OD) δ (ppm) : 206.7, 174.6, 149.5, 148.4, 147.7, 144.7, 144.5, 139.6, 136.6, 132.2, 131.9, 130.8 (2C), 129.8, 129.6, 129.5 (2C), 129.4, 129.0, 128.4, 128.2, 124.2, 119.6, 105.6, 80.5, 76.3, 74.2, 72.5, 71.7, 71.6, 68.6, 62.5, 59.8, 52.4, 50.4, 48.3, 46.5, 42.9, 42.1 (2C), 40.5, 34.9, 34.2, 26.2 (2C), 18.1, 17.9, 13.3, 10.0, 9.8. HRMS (ESI) m/z :897.5111 [M+H]+, calcd for CsffeNeOo: 897.5126. YT710
Figure imgf000092_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT650 (100.0 mg, 0.154 mmol) with 6-azidoquinoline (39.1 mg, 0.230 mmol) was converted to YT710 (115.3 mg, 91%) as a pale yellow solid.
¾ NMR (500 MHz, CD3OD) δ (ppm) : 8.96 (dd, J = 1.7, 4.0 Hz, 1H), 8.85 (s, 1H), 8.56-8.53 (m, 2H), 8.42 (dd, J = 2.3, 9.2 Hz, 1H), 8.27 (d, J = 9.2 Hz, 1H), 7.66 (dd, J = 4.3, 8.0 Hz, 1H), 7.18 (d, J = 14.9 Hz, 1H), 6.49 (d, J = 15.5 Hz, 1H), 5.63 (d, J = 10.9 Hz, 1H), 4.68 (m, 1H), 4.21 (d, J = 7.5 Hz, 1H), 3.91 (d, J = 13.8 Hz, 1H), 3.86 (d, J = 9.7 Hz, 1H), 3.59-3.53 (complex m, 2H), 3.47 (dd, J = 3.4 , 10.9 Hz, 1H), 3.36-3.30 (complex m, 2H), 3.20 (m, 1H), 3.12 (app t, J= 9.5 Hz, 1H), 2.87-2.76 (complex m, 2H), 2.67 (m, 1H), 2.50 (s, 6H), 2.47-2.26 (complex m, 3H), 2.24 (s, 3H), 1.82 (s, 3H), 2.06 (d, J =16.6 Hz, 1H), 1.82-1.67 (complex m, 5H), 1.58-1.50 (complex m, 3H), 1.22 (app d, J = 6.3 Hz, 6H), 1.02 (d, J = 6.9 Hz, 3H), 0.89 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.6, 174.3, 152.4, 149.6, 148.2, 146.5, 144.7, 138.8, 136.5, 136.4, 131.3, 129.9, 124.6, 123.9, 123.8, 120.4, 119.5, 105.7, 80.6, 76.1, 74.3, 72.6, 71.7 (2C), 68.4, 62.4, 55.8, 52.9, 48.2, 46.6, 43.1, 42.5, 42.2 (2C), 40.5, 35.0, 34.2, 26.2, 26.0, 18.2, 17.9, 13.2, 10.0, 9.7. HRMS (ESI) m/z :821.4815 [M+H]+, calcd for C44H65N6O9: 821.4813. YT713
Figure imgf000093_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT699 (100.0 mg, 0.133 mmol) with propargyl benzoate (24.6 μΐ., 0.170 mmol) was converted to YT713 (93.3 mg, 67%) as a pale yellow solid. HRMS (ESI) m/z : 1044.4190 [M+H]+, calcd for C50H71IN5O11: 1044.4195.
YT714
Figure imgf000093_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (100.0 mg, 0.113 mmol) with 3-ethynylquinoline (26.0 mg, 0.170 mmol) was converted to YT714 (64.8 mg, 56%) as a pale yellow solid. HRMS (ESI) m/z : 1037.4252 [M+H]+, calcd for C51H70IN6O9: 1037.4249. YT715
Figure imgf000094_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT615 (100.0 mg, 0.150 mmol) with w-ethynyl aniline (35.1 mg, 0.299 mmol) was converted to YT715 (33.0 mg, 28%) as a pale yellow solid. HRMS (FAB, NBA matrix) m/z :785.4808 [M+H]+, calcd for C^HesNeOo: 785.4813.
YT716
Figure imgf000094_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT615 (100.0 mg, 0.150 mmol) with 2-ethynylpyridine (30.8 mg, 0.299 mmol) was converted to YT716 (50.9 mg, 44%) as a pale yellow solid. HRMS (FAB, NBA matrix) m/z :771.4676 [M+H]+, calcd for C40H63N6O9: 771.4657. YT717
Figure imgf000095_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT615 (100.0 mg, 0.150 mmol) with 3-ethynylthiophene (29.5 μΐ,, 0.299 mmol) was converted to YT717 (65.9 mg, 57%) as a colorless solid. HRMS (FAB, NBA matrix) m/z :776.4270 [M+H]+, calcd for C39H62N5O9S: 776.4268.
YT718
Figure imgf000095_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT615 (100.0 mg, 0.150 mmol) with l-ethynyl-2-nitrobenzene (44.0 mg, 0.299 mmol) was converted to YT718 (55.4 mg, 45%) as a pale yellow solid. HRMS (FAB, NBA matrix) m/z :815.4567 [M+H]+, calcd for C4iH63N60ii: 815.4555. YT721
Figure imgf000096_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT615 (100.0 mg, 0.150 mmol) with 4-ethynylbiphenyl (53.5 mg, 0.30 mmol) was converted to YT721 (79.6 mg, 63%) as a colorless solid. ¾ NMR (500 MHz, CD3OD) δ (ppm) : 8.51 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H), 7.71 (d, J = 8.6 Hz, 2H), 7.66 (m, 2H), 7.45 (m, 2H), 7.35 (m, 1H), 7.32 (d, J = 15.5 Hz, 1H), 6.48 (d, J = 15.5 Hz, 1H), 5.94 (d, J= 10.9 Hz, 1H), 4.95 (m, 1H), 4.60 (m, 2H), 4.23 (d, J= 7.5 Hz, 1H), 3.80 (d, J= 9.7 Hz, 1H), 3.67 (complex m, 2H), 3.62 (d, J = 10.3 Hz, 1H), 3.33 (m, 1H), 3.20-3.06 (complex m, 4H), 2.86 (m, 1H), 2.74-2.62 (complex m, 3H), 2.49 (s, 6H), 2.47 (m, 1H), 2.36 (m, 1H), 2.07 (d, J= 16.6 Hz, 1H), 1.93-1.42 (complex m, 8H), 1.86 (s, 3H), 1.21 (d, J= 6.9 Hz, 3H), 1.16 (d, J= 5.7 Hz, 3H), 1.04 (d, J = 6.9 Hz, 3H), 0.94 (t, J = 7.5 Hz, 3H); HRMS (ESI) m/z :846.5011 [M+H]+, calcd for C47H68N5O9: 846.5017.
YT722
Figure imgf000097_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT615 (100.0 mg, 0.150 mmol) with l-ethynyl-4-pentylbenzene (51.5 mg, 0.299 mmol) was converted to YT722 (57.6 mg, 46%) as a colorless solid. HRMS (ESI) m/z :840.5508 [M+H]+, calcd for C46H74N5O9: 840.5487.
YT723
Figure imgf000097_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT615 (36.0 mg, 0.054 mmol) with l-ethynyl-2,4,5-trimethylbenzene (15.5 mg, 0.108 mmol) was converted to YT723 (31 mg, 71%) as a colorless solid. HRMS (ESI) m/z :834.4984 [M+Na]+, calcd for C44H69N509Na: 834.4993. YT724
Figure imgf000098_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT615 (100.0 mg, 0.150 mmol) with / i-butylphenylacetylene (53.4 μΐ,, 0.299 mmol) was converted to YT724 (70.5 mg, 57%) as a colorless solid. HRMS (FAB, NBA matrix) m/z :826.5333 [M+H]+, calcd for C45H72N5O9: 826.5330.
YT726
Figure imgf000098_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (20.0 mg, 0.0321 mmol) with 3-ethynylthiophene (4.7 μΐ,, 0.0481 mmol) was converted to YT726 (18.8 mg, 80%) as a colorless solid. HRMS (ESI) m/z :733.3838 [M+H]+, calcd for C37H57N4O9S: 733.3846. YT727
Figure imgf000099_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (70.0 mg, 0.112 mmol) with ethynylbenzene (18.5 L, 0.168 mmol) was converted to YT727 (54.6 mg, 67%) as a colorless solid. HRMS (ESI) m/z :749.4109 [M+Na]+, calcd for
Figure imgf000099_0002
749.4102.
YT728
Figure imgf000099_0003
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (70.0 mg, 0.112 mmol) with 4-ethynylquinoline (25.8 mg, 0.168 mmol) was converted to YT728 (67.7 mg, 73%) as a colorless solid. HRMS (ESI) m/z :800.4222 [M+H]+, calcd for C42H59N509Na: 800.4211. YT731
Figure imgf000100_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT699 (100.0 mg, 0.150 mmol) with propargyl benzoate (47.9 mg, 0.299 mmol) was converted to YT731 (64.0 mg, 52%) as a colorless solid. HRMS (FAB, NBA matrix) m/z :828.4774 [M+H]+, calcd for C43H66N5O11 : 828.4779.
YT732
Figure imgf000100_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT615 (100.0 mg, 0.149 mmol) with l-ethynyl-3-quinoline (45.8 mg, 0.299 mmol) was converted to YT732 (66.0 mg, 54%) as a colorless solid. ¾ NMR (500 MHz, CD3OD) δ (ppm) : 9.39 (d, J = 2.3 Hz, 1H), 8.81 (d, J = 2.3 Hz, 1H), 8.75 (s, 1H), 8.06 (d, J= 8.6 Hz, 1H), 8.02 (d, J= 8.0 Hz, 1H), 7.79 (m, 1H), 7.65 (app. t, J = 7.5 Hz, 1H), 7.28 (d, J = 15.5 Hz, 1H), 6.47 (d, J = 15.5 Hz, 1H), 5.92 (d, J = 10.3 Hz, 1H), 4.92 (m, 1H), 4.65 (m, 2H), 4.23 (d, J = 7.5 Hz, 1H), 3.79 (d, J = 9.7 Hz, 1H), 3.65-3.61 (complex m, 3H), 3.33 (m, 1H), 3.23-3.08 (complex m, 4H), 2.85 (m, 1H), 2.75 (m, 1H), 2.69-2.63 (complex m, 2H), 2.50 (s, 6H), 2.48-2.35 (complex m, 2H), 2.06 (d, J = 16.6 Hz, 1H), 1.91-1.43 (complex m, 8H), 1.85 (s, 3H), 1.21 (d, J = 6.9 Hz, 3H), 1.18 (d, J = 6.3 Hz, 3H), 1.03 (d, J = 6.3 Hz, 3H), 0.93 (t, J = 7.5 Hz, 3H); HRMS (ESI) m/z :821.4808 [M+H]+, calcd for C44H65N6O9: 821.4813.
YT733
Figure imgf000101_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (70.0 mg, 0.112 mmol) with 3-ethynylquinoline (25.8 mg, 0.168 mmol) was converted to YT733 (55.1 mg, 58%) as a colorless solid. HRMS (ESI) m/z :800.4220 [M+Na]+, calcd for C42H59N509Na: 800.4211.
YT734
Figure imgf000102_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (77.0 mg, 0.123 mmol) with 2-ethynylquinoline (28.4 mg, 0.185 mmol) was converted to YT734 (90.2 mg, 94%) as a colorless solid. HRMS (ESI) m/z :800.4221 [M+Na]+, calcd for C42H59N509Na: 800.4211.
YT735
Figure imgf000102_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (66.6 mg, 0.107 mmol) with 4-ethynylpyridine (16.5 mg, 0.160 mmol) was converted to YT735 (52.4 mg, 68%) as a colorless solid. HRMS (ESI) m/z :750.4058 [M+Na]+, calcd for CssHs NsOgNa: 750.4054. YT736
Figure imgf000103_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT616 (70 mg, 0.112 mmol) with 3-ethynylpyridine (17.4 mg, 0.168 mmol) was converted to YT736 (61.2 mg, 69%) as a colorless solid. 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.4, 175.6, 150.2, 150.0, 148.4, 146.0, 144.8, 137.3, 136.1, 129.6, 126.5, 123.7, 120.3, 105.8, 80.2, 79.3, 77.1, 75.1, 73.3, 72.5, 72.4, 68.8, 63.4, 50.0, 49.0, 47.0, 43.0 (2C), 41.5, 35.4, 34.3, 30.0, 27.0, 19.0, 18.4, 14.0, 10.8, 10.2.
YT737
Figure imgf000103_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT711 (100.0 mg, 0.138 mmol) with 6-azidoquinoline (35.1 mg, 0.206 mmol) was converted to YT737 (92.5 mg, 75%) as a pale yellow solid. HRMS (ESI) m/z :897.5116 [M+H]+, calcd for CsoifeNeOo: 897.5126. YT738
Figure imgf000104_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with 5-azidoisoquinoline (39.1 mg, 0.230 mmol) was converted to YT738 (89.2 mg, 71%) as a pale yellow solid. lH NMR (500 MHz, CD3OD) δ (ppm) : 9.44 (d, J = 1.2 Hz, 1H), 8.71 (s, 1H), 8.57 (d, J= 6.3 Hz, 1H), 8.40 (d, J= 8.6 Hz, 1H), 8.13 (dd, J= 1.2, 7.5 Hz, 1H), 8.13 (t, J= 7.7 Hz, 1H), 7.74 (d, J = 5.7 Hz, 1H), 7.07 (d, J= 15.5 Hz, 1H), 6.44 (d, J = 15.5 Hz, 1H), 5.21 (d, J = 10.3 Hz, 1H), 4.25 (d, J= 7.5 Hz, 1H), 4.15 (m, 1H), 3.95 (dd, J= 1.7, 9.7 Hz, 1H), 3.86 (d, J= 13.8 Hz, 1H), 3.80 (d, J = 10.3 Hz, 1H), 3.58-3.53 (m, 2H), 3.49 (dd, J = 4.0 , 10.9 Hz, 1H), 3.38-3.23 (complex m, 2H), 3.14 (app t, J = 9.5 Hz, 1H), 2.86 (m, 1H), 2.74-2.63 (complex m, 2H), 2.51 (s, 6H), 2.42-2.28 (complex m, 3H), 2.25 (s, 3H), 1.97 (d, J=17.2 Hz, 1H), 1.91-1.42 (complex m, 8H), 1.76 (s, 3H), 1.26 (d, J= 6.3 Hz, 3H), 1.21 (d, J = 6.9 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.74 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.5, 173.9, 153.7, 149.6, 145.8, 145.0, 144.8, 136.2, 134.3, 132.7, 131.4, 130.5, 129.9, 128.6, 128.1, 119.2, 117.6, 105.7, 80.7, 76.1, 74.3, 72.6, 71.7 (2C), 68.3, 62.4, 56.1, 52.5, 48.3, 46.7, 43.0, 42.7, 42.2 (2C), 40.1, 35.0, 34.1, 26.2, 25.9, 18.3, 17.9, 13.1, 9.9, 9.6. HRMS (ESI) m/z :821.4813 [M+H]+, calcd for C44H65N6O9: 821.4813. YT739
Figure imgf000105_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT712 (100.0 mg, 0.157 mmol) with 3-azidoquinoline (40.1 mg, 0.236 mmol) was converted to YT739 (97.9 mg, 77%) as a colorless solid. [a]26 D -111.2 (c 1.0, CHC13); ¾ NMR (500 MHz, CD3OD) δ (ppm) : 9.48 (d, J = 2.9 Hz, 1H), 8.89 (d, J = 2.3 Hz, 1H), 8.82 (s, 1H), 8.16 (d, J = 8.6 Hz, 1H), 8.13 (d, J = 8.6 Hz, 1H), 7.88 (dt, J = 1.2, 8.0 Hz, 1H), 7.74 (dt, J = 1.2, 8.0 Hz, 1H), 7.23 (d, J = 14.9 Hz, 1H), 6.48 (d, J = 15.5 Hz, 1H), 5.70 (d, J = 10.3 Hz, 1H), 4.63 (app t, J = 8.6 Hz, 1H), 4.26 (d, J = 7.5 Hz, 1H), 4.00 (d, J = 14.3 Hz, 1H), 3.86 (d, J = 13.8 Hz, 1H), 3.80 (d, J = 10.3 Hz, 1H), 3.65 (d, J = 10.3 Hz, 1H), 3.51 (dd, J = 3.4 , 11.2 Hz, 1H), 3.41-3.22 (complex m, 3H), 3.14 (t, J = 9.2, 9.7 Hz, 1H), 2.92 (m, 1H), 2.83-2.73 (complex m, 2H), 2.66 (m, 1H), 2.51 (s, 6H), 2.45-2.38 (complex m, 2H), 2.04 (d, J =17.2 Hz, 1H), 1.89-1.66 (complex m, 5H), 1.82 (s, 3H), 1.60-1.45 (complex m, 3H), 1.24 (d, J= 6.3 Hz, 3H), 1.22 (d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H), 0.84 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.7, 174.6, 149.7, 148.4, 148.3, 144.8 (2C), 136.6, 132.2, 131.9, 129.8, 129.6, 129.4, 129.0, 128.4, 123.2, 119.6, 105.7, 80.6, 76.2, 74.3, 72.6, 71.73, 71.69, 68.3, 62.5, 48.3, 47.1, 46.6, 44.5, 42.8, 42.2 (2C), 40.4, 34.7, 34.1, 27.8, 26.1, 18.2, 17.9, 13.2, 10.0, 9.7. HRMS (ESI) m/z :829.4478 [M+Na]+, calcd for C43H62N609Na: 829.4476. YT740
Figure imgf000106_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (100.0 mg, 0.1 13 mmol) with l -ethynyl-2-nitrobenzene (33.3 mg, 0.226 mmol) was converted to YT740 (62.2 mg, 53%) as a colorless solid. HRMS (ESI) m/z : 1053.3832 [M+Na]+, calcd for C48H67lN60i iNa: 1053.3810.
YT741
Figure imgf000106_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (100.0 mg, 0.1 13 mmol) with 3-ethynylpyridine (23.3 mg, 0.226 mmol) was converted to YT741 (71.7 mg, 64%) as a colorless solid. HRMS (ESI) m/z : 1009.3934 [M+H]+, calcd for C49H66lN609: 1009.3936. YT742
Figure imgf000107_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (100.0 mg, 0.113 mmol) with w-ethynylaniline (25.5 mL, 0.226 mmol) was converted to YT742 (75.6 mg, 67%) as a colorless solid. HRMS (ESI) m/z : 1023.4071 [M+Na]+, calcd for C48H69lN609Na: 1023.4068.
YT743
Figure imgf000107_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with 5-azidoquinoline (39.1 mg, 0.230 mmol) was converted to YT743 (113.2 mg, 90%) as a pale yellow solid. ¾ NMR (500 MHz, CD3OD) δ (ppm) : 9.00 (dd, J = 1.7, 4.0 Hz, 1H), 8.69 (s, 1H), 8.30 (d, J= 8.6 Hz, 1H), 8.25 (d, J= 8.6 Hz, 1H), 8.02 (app t, J = 8.0 Hz, 1H), 7.94 (d, J = 7.5 Hz, 1H), 7.66 (dd, J = 4.0, 8.6 Hz, 1H), 7.06 (d, J = 15.5 Hz, 1H), 6.43 (d, J = 15.5 Hz, 1H), 5.11 (d, J = 10.3 Hz, 1H), 4.25 (d, J= 7.5 Hz, 1H), 4.03 (m, 1H), 3.95 (d, J= 13.8 Hz, 1H), 3.79 (dd, J= 1.2, 9.7 Hz, 1H), 3.58-3.47 (complex m, 3H), 3.36 (dd, J = 7.5, 10.9 Hz, 1H), 3.30-3.23 (complex m, 2H), 3.14 (app t, J = 9.5 Hz, 1H), 2.86 (m, 1H), 2.72-2.62 (complex m, 2H), 2.51 (s, 6H), 2.41-2.26 (complex m, 3H), 2.25 (s, 3H), 1.95 (d, J=17.2 Hz, 1H), 1.92-1.40 (complex m, 8H), 1.75 (s, 3H), 1.26 (d, J= 6.3 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.76 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.4, 173.8, 152.5, 149.6, 148.9, 145.7, 136.2, 135.2, 133.9, 131.7, 130.4, 128.2, 125.8, 125.5, 124.1, 119.1, 105.7, 80.7, 76.0, 74.3, 72.3, 72.6, 71.72, 71.65, 68.2, 62.3, 56.0, 52.4, 48.4, 46.7, 42.9, 42.8, 42.2 (2C), 40.1, 35.0, 34.0, 26.1, 28.9, 18.3, 17.9, 13.1, 10.0, 9.6. HRMS (ESI) m/z :821.4814 [M+H]+, calcd for C44H65N6O9: 821.4813.
YT744
Figure imgf000108_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with 1 -azidonaphthalene (39.1 mg, 0.230 mmol) was converted to YT744 (110 mg, 87%) as a pale yellow solid. lH NMR (500 MHz, CD3OD) δ (ppm) : 8.62 (s, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.07 (m, 1H), 7.76 (dd, J = 1.2, 7.5 Hz, 1H), 7.70 (m, 1H), 7.66-7.58 (complex m, 3H), 7.09 (d, J = 15.5 Hz, 1H), 6.43 (d, J = 14.9 Hz, 1H), 5.06 (d, J = 10.3 Hz, 1H), 4.25 (d, J = 7.5 Hz, 1H), 4.15 (app t, J = 8.6 Hz, 1H), 3.96 (dd, J= 1.2, 9.7 Hz, 1H), 3.58 (d, J= 10.3 Hz, 1H), 3.52 (d, J= 13.8 Hz, 1H), 3.45 (dd, J = 4.6 , 10.9 Hz, 1H), 3.35 (dd, J = 7.5 , 10.3 Hz, 1H), 3.28-3.20 (complex m, 2H), 3.14 (app t, J = 9.5 Hz, 1H), 2.87 (m, 1H), 2.72-2.63 (complex m, 2H), 2.51 (s, 6H), 2.41-2.26 (complex m, 3H), 2.25 (s, 3H), 1.95 (d, J=17.2 Hz, 1H), 1.91-1.38 (complex m, 8H), 1.74 (s, 3H), 1.26 (d, J= 5.7 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.76 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.4, 173.7, 149.7, 145.4, 145.2, 136.2, 135.5, 135.3, 131.6, 130.1, 129.4, 129.0, 128.4, 128.3, 126.3, 125.4, 123.7, 119.0, 105.7, 80.7, 76.0, 74.3, 72.6, 71.74, 71.65, 68.3, 62.4, 56.0, 52.5, 48.4, 46.7, 42.9, 42.8, 42.2 (2C), 40.1, 35.0, 34.0, 26.2, 26.0, 18.3, 17.9, 13.1, 10.0, 9.6. HRMS (ESI) m/z :820.4868 [M+H]+, calcd for C44H66N5O9: 820.4861.
YT745
Figure imgf000109_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT712 (100.0 mg, 0.157 mmol) with 6-azidonaphthalene (40.1 mg, 0.236 mmol) was converted to YT745 (100.2 mg, 79%) as a colorless solid. ¾ NMR (500 MHz, CD3OD) δ (ppm) : 8.95 (dd, J = 1.7, 8.0 Hz, 1H), 8.77 (s, 1H), 8.53 (m, 2H), 8.42 (dd, J = 2.3, 9.2 Hz, 1H), 8.25 (d, J = 9.2, 1H), 7.65 (dd, J = 43, 8.3 Hz, 1H), 7.25 (d, J = 15.5 Hz, 1H), 6.49 (d, J= 15.5 Hz, 1H), 5.76 (d, J= 10.3 Hz, 1H), 4.76 (m, 1H), 4.25 (d, J = 7.5 Hz, 1H), 3.99 (d, J= 13.8 Hz, 1H), 3.86 (d, J= 13.8 Hz, 1H), 3.81 (d, J= 9.7 Hz, 1H), 3.66 (dd, J= 10.3 Hz, 1H), 3.53 (dd, J = 3.4 , 11.5 Hz, 1H), 3.46 (m, 1H), 3.35 (dd, J = 8.0, 10.9 Hz, 1H), 3.23 (m, 1H), 3.13 (app t, J = 9.5 Hz, 1H), 2.90 (m, 1H), 2.84-2.74 (complex m, 2H), 2.67 (m, 1H), 2.51 (s, 6H), 2.47- 2.36 (complex m, 2H), 2.06 (d, J =17.2 Hz, 1H), 1.88-1.68 (complex m, 5H), 1.83 (s, 3H), 1.60-1.51 (complex m, 3H), 1.23 (d, J= 6.3 Hz, 3H), 1.22 (d, J= 6.9 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.88 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.4, 173.7, 149.7, 145.4, 145.2, 136.2, 135.5, 135.3, 131.6, 130.1, 129.4, 129.0, 128.4, 128.3, 126.3, 125.4, 123.7, 119.0, 105.7, 80.7, 76.0, 74.3, 72.6, 71.74, 71.65, 68.3, 62.4, 56.0, 52.5, 48.4, 46.7, 42.9, 42.8, 42.2 (2C), 40.1, 35.0, 34.0, 26.2, 26.0, 18.3, 17.9, 13.1, 10.0, 9.6. HRMS (ESI) m/z :829.4480 [M+Na]+, calcd for C43H62N609Na: 829.4476. YT747
Figure imgf000110_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with 1 -azidoadamantane (40.9 mg, 0.230 mmol) was converted to YT747 (110.6 mg, 87%) as a colorless solid. HRMS (ESI) m/z :828.5474 [M+H]+, calcd for C45H74N5O9: 828.5487.
YT749
Figure imgf000110_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (80.0 mg, 0.0905 mmol) with cyclopropylacetylene (30.4 mg, 0.181 mmol) was converted to YT749 (54.4 mg, 63%) as a colorless solid. HRMS (ESI) m/z :972.3968 [M+Na]+, calcd for C45H68lN509Na: 972.3959. YT750
Figure imgf000111_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (80.0 mg, 0.0905 mmol) with 4-ethynylbiphenyl (32.3 mg, 0.181 mmol) was converted to YT750 (53.5 mg, 56%) as a colorless solid. HRMS (ESI) m/z : 1084.4274 [M+Na]+, calcd for Cs^INsC^Na: 1084.4272.
YT751
Figure imgf000111_0002
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (100.0 mg, 0.113 mmol) with / i-butylacetylene (40.0 μΕ, 0.225 mmol) was converted to YT751 (60.8 mg, 65%) as a pale yellow solid. HRMS (ESI) m/z : 1042.4772 [M+H]+, calcd for C52H77IN5O9: 1042.4766. YT752
Figure imgf000112_0001
According to the general procedure (method A) for synthesis of triazole analogues, YT699 (100.0 mg, 0.113 mmol) with l-ethynyl-4-n-pentylbenzene (44 \L, 0.227 mmol) was converted to YT752 (60.7 mg, 64%) as a pale yellow solid. HRMS (ESI) m/z : 1056.4936 [M+H]+, calcd for C53H79IN5O9: 1056.4922.
YT755
Figure imgf000112_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT711 (100.0 mg, 0.138 mmol) with 5-azidoquinoline (30.4 mg, 0.179 mmol) was converted to YT755 (96.5 mg, 78%) as a colorless solid. HRMS (ESI) m/z :897.5115 [M+H]+, calcd for C5oH69N609: 897.5126 YT756
Figure imgf000113_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT711 (100.0 mg, 0.138 mmol) with 5-azidoisoquinoline (30.4 mg, 0.179 mmol) was converted to YT756 (75.1 mg, 61%) as a pale yellow solid. HRMS (ESI) m/z :897.5121 [M+H]+, calcd for CsoifeNeOo: 897.5126.
YT757
Figure imgf000113_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT711 (100.0 mg, 0.138 mmol) with 1 -azidonaphthalene (30.4 mg, 0.179 mmol) was converted to YT757 (110.2 mg, 89%) as a pale yellow solid. HRMS (ESI) m/z :896.5176 [M+H]+, calcd for C5iH7oN509Na: 896.5174. YT758
Figure imgf000114_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT712 (100.0 mg, 0.157 mmol) with 5-azidoquinoline (40.1 mg, 0.236 mmol) was converted to YT758 (88.2 mg, 70%) as a pale brown solid. HRMS (ESI) m/z : 829.4479 [M+Na]+, calcd for C43H62N609Na: 829.4476.
YT759
Figure imgf000114_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT712 (100.0 mg, 0.157 mmol) with 1 -azidonaphthalene (40.1 mg, 0.236 mmol) was converted to YT759 (97.3 mg, 77%) as a pale yellow solid. HRMS (ESI) m/z :828.4515 [M+Na]+, calcd for C44H63N509Na: 828.4524. YT760
Figure imgf000115_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT646 (100.0 mg, 0.154 mmol) with 2-azidonaphthalene (34.5 mg, 0.204 mmol) was converted to YT760 (95.0 mg, 76%) as a colorless solid. HRMS (ESI) m/z :820.4858 [M+H]+, calcd for C45H66N5O9: 820.4861.
YT761
Figure imgf000115_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT712 (100.0 mg, 0.157 mmol) with 5-azidoisoquinoline (40.1 mg, 0.236 mmol) was converted to YT761 (87.8 mg, 69%) as a pale yellow solid. HRMS (ESI) m/z :807.4652 [M+H]+, calcd for C43H63N6O9: 807.4657. YT762
Figure imgf000116_0001
According to the general procedure (method B) for synthesis of triazole analogues, YT711 (100.0 mg, 0.138 mmol) with 2-azidonaphthalene (30.4 mg, 0.179 mmol) using was converted to YT762 (120.0 mg, 97%) as a pale brown solid. 13C NMR (125 MHz, CD3OD) δ (ppm) : 206.7, 174.6, 149.4, 147.2, 147.2, 144.3, 139.7, 135.8, 134.6, 134.3, 131.0, 130.7 (2C), 129.6, (2C), 129.5, 129.0, 128.4, 128.15, 128.06, 123.7, 120.1, 119.6 (2C), 105.5, 80.2, 76.2, 74.1, 72.5, 71.6 (2C), 68.6, 62.5, 59.7, 52.1, 50.6, 48.2, 46.5, 42.8, 42.1 (2C), 40.5, 34.8, 34.0, 26.3, 26.1, 18.1, 17.9, 13.4, 10.1, 9.9. HRMS (ESI) m/z :896.5177 [M+H]+, calcd for C51H70N5O9: 896.5174
YT763
Figure imgf000116_0002
According to the general procedure (method B) for synthesis of triazole analogues, YT712 (100.0 mg, 0.157 mmol) with 2-azidonaphthalene (34.5 mg, 0.204 mmol) was converted to YT763 (92.1 mg, 73%) as a pale brown solid. HRMS (ESI) m/z: 806.4704 [M+H]+, calcd for C44H64N5O9: 806.4704 Synthesis of amine analogues at C23 position
YT729
Figure imgf000117_0001
To a solution of YT650 (300 mg, 0.365 mmol) in anhydrous pyridine (5.3 mL) was added DPPA (94.3 μL, 0.438 mmol) and DBU (65.5 μL, 0.438 mmol) at 0 °C and the reaction mixture was stirred at 0 °C for 2 hr. Then DPPA (175 ^L, 0.814 mmol) and DBU (109 0.718 mmol) were added again to the reaction mixture and the reaction was further performed at 80°C for 4 hr. The reaction was quenched with saturated NaHC03 aq. (2 mL), the reaction mixture was concentrated under reduced pressure. The residue was added CHCI3 (8 mL) and washed with saturated NaHCOsaq. The organic layer was dried over Na2S04, and concentrated in vacuo. The crude product was used for the next step without further purification. To the solution of the crude product (182 mg, 0.173 mmol) in anhydrous DMF (1.9 mL) was added NaNb (33.7 mg, 0.519 mmol), and the reaction mixture was stirred at 80°C for 22 hr. The solution was extracted with Hexane/EtOAc (v/v 1/1, 5 mL x 2), and washed with H2O (15 mL). The organic layer was dried over Na2S04 and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (CHCl3/MeOH/NH3, 60/1/0.15) to give YT729 (115mg, 79%) as a colorless solid. HRMS (ESI) m/z: 846.4877 [M+H]+, calcd for C44H64N9O8: 846.4878.
YT768
Figure imgf000118_0001
To a solution of YT650 (300 mg, 0.365 mmol) and PPI13 (288 mg, 1.10 mmol) in anhydrous pyridine (5.3 mL) was added iodine (186 mg, 0.731 mmol) in anhydrous pyridine (2 mL), and the reaction mixture was stirred at 0 °C for 2 hr. The reaction was quenched with MeOH (0.2 mL), added toluene (15 mL) and concentrated in vacuo. The residue was added CHCI3 (8 mL) and washed with saturated NaS203aq. The organic layer was dried over Na2SO i, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (CHCL/MeOH/NL , 70/1/0.15) to give compound YT768 (290 mg, 85%) as a colorless solid. lH NMR (500 MHz, CD3OD) d (ppm) : 9.49 (d, J = 2.3 Hz, 1H), 8.91 (d, J = 1.7 Hz, 1H), 8.89 (s, 1H), 8.18 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 7.90 (m, 1H), 7.76 (t, J = 8.0 Hz, 1H), 7.05 (d, J = 15.5 Hz, 1H), 6.49 (d, J = 14.9 Hz, 1H), 5.10 (d, J = 10.3 Hz, 1H), 4.32 (m, 1H), 4.25 (d, J= 7.5 Hz, 1H), 3.92 (d, J= 14.3 Hz, 1H), 3.81 (dd, J= 1.2, 9.7 Hz, 1H), 3.58 (d, J = 10.7 Hz, 1H), 3.51 (d, J = 13.8 Hz, 1H), 3.35 (dd, J = 7.5, 10.3 Hz, 1H), 3.29-3.22 (complex m, 2H), 3.14 (t, J= 9.5, 1H), 3.09 (dd, J = 3.2, 10.0 Hz, 1H), 2.84 (m, 1H), 2.74 (m, 1H), 2.67 (m, 1H), 2.50 (s, 6H), 2.44-2.30 (complex m, 3H), 2.25 (s, 3H), 2.02 (d, J =16.6 Hz, 1H), 1.90-1.77 (complex m, 3H), 1.77 (s, 3H), 1.70-1.62 (complex m, 2H), 1.58-1.41 (complex m, 3H), 1.24 (d, J = 6.3 Hz, 3H), 1.22 (d, J= 6.9 Hz, 3H), 1.02 (d, J= 6.3 Hz, 3H), 0.85 (t, J= 7.2 Hz, 3H). 13C NMR (125 MHz, CD3OD) d (ppm) : 206.3, 174.1, 148.9, 148.4, 147.2, 146.9, 145.4, 145.3, 136.7, 132.3, 132.1, 129.9, 129.8, 129.5, 129.3, 129.0, 124.3, 120.0, 105.7, 80.7, 77.8, 74.3, 72.6, 71.72, 71.66, 68.3, 56.0, 47.2, 46.6, 43.0, 42.9, 42.2 (2C), 40.3, 34.9, 34.1, 26.2, 25.4, 18.3, 17.8, 13.2, 9.8, 9.7, 5.1. HRMS (ESI) m/z: 931.3828 [M+H]+, calcd for C44H64lN6C>8: 931.3830. YT769
Figure imgf000119_0001
To a solution of YT768 (20.0 mg, 21.5 μηιοΐ) in anhydrous acetonitrile (0.3 mL) was added piperidine (21.5 μΐ , 0.215 mmol). The mixture was heated in a microwave reactor at 120°C for 1.5 hours. Then piperidine (42.0 μΐ^, 0.430 mmol) was added again to the reaction mixture and the reaction was further performed in a microwave reactor at 80°C for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was purified by flash column chromatography on silica gel (CHCyMeOH/NLh, 60/1/0.15) to give compound YT769 (17.0 mg, 89%) as a pale yellow solid. HRMS (FAB, NBA matrix) m/z 888.5588 [M+H]+, calcd for C49H74N7O8: 888.5599.
YT770
Figure imgf000119_0002
To a solution of YT768 (80.0 mg, 85.9 μιηοΐ) in anhydrous acetonitrile (1.1 mL) was added dimethylamine (40 wt% in water, 0.8 mL). The mixture was heated in a microwave reactor at 80°C for 1 hour. The solvent mixture was concentrated in vacuo, and the residue was purified by flash column chromatography on silica gel (CHCl3/MeOH/NH3, 60/1/0.15) to give YT770 (69.2 mg, 95%) as a pale yellow solid. ¾ NMR (500 MHz, CD3OD) d (ppm) : 9.51(d, J = 2.9 Hz, 1H), 8.91 (d, J = 2.3 Hz, 1H), 8.19 (d, J= 8.6 Hz, 1H), 8.14 (d, J= 8.0 Hz, 1H) , 7.91 (m, 1H), 7.77 (m, 1H), 7.03 (d, J= 14.9 Hz, 1H), 6.44 (d, J= 15.5 Hz, 1H), 5.12 (d, J = 10.3 Hz, 1H), 4.26 (d, J = 7.5 Hz, 1H), 4.19 (m, 1H), 3.97 (d, J = 14.3 Hz, 1H), 3.85 (m, 1H), 3.60 (d, J = 10.3 Hz, 1H), 3.43 (d, J = 14.3 Hz, 1H), 3.36 (dd, J = 7.5 , 10.3 Hz, 1H), 3.26 (m, 1H), 3.26 (m, 1H), 3.15 (d, J= 9.5 Hz, 1H), 2.89 (m, 1H), 2.78-2.62 (complex m, 2H), 2.52 (s, 6H), 2.45-2.39 (complex m, 2H), 2.31 (m, 1H), 2.25 (s, 3H), 2.06-2.02 (m, 1H), 2.02(s, 6H), 1.94-1.74 (complex m, 4H), 1.78 (s, 3H), 1.73-1.66 (complex m, 2H), 1.63-1.40 (complex m, 3H), 1.25 (d, J= 6.3 Hz, 3H), 1.20 (d, J= 6.9 Hz, 3H), 1.02 (d, J= 6.3 Hz, 3H), 0.84 (t, J= 7.5 Hz, 3H). 13C NMR (125 MHz, CD3OD) d (ppm) : 206.2, 174.3, 149.3, 148.6, 147.2, 146.1, 145.7, 135.9, 132.3, 132.1, 130.0, 129.9, 129.5 (2C), 129.0, 124.1, 119.3, 105.7, 80.5, 76.9, 74.3, 72.6, 71.73, 71.70, 68.4, 61.1, 56.1, 52.4, 46.7, 45.8 (2C), 44.0, 43.2, 43.0, 42.2 (2C), 40.2, 34.8, 33.8, 26.2, 26.1, 18.2, 17.8, 13.1, 9.8, 9.7. HRMS (FAB, NBA matrix) m/z: 848.5277 [M+H]+, Calcd for C46H70N7O8: 848.5286.
YT771
Figure imgf000120_0001
To a solution of YT729 (90.0 mg, 0.106 mmol) in THF/H2O (1.2/0.12 mL) was added PPh3 (94.4 mg, 0.361 mmol), and the reaction mixture was stirred at room temperature for 25 hr. The reaction mixture was concentrated in vacuo and the residue was extracted with CHCI3 (5 mL χ 2). The organic layers were washed with brine (3 mL x 1), and dried over Na2S04, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (CHCk/MeOH/NHs, 60/1/0.15) to give compound YT771 (57.0 mg, 65%) as a colorless solid. HRMS (FAB, NBA matrix) m/z: 820.4973 [M+H]+, calcd for C44H66N708: 820.4973. Paper disc assays
(1) Antibacterial activities against Mannheimia and Pasteurella were determined by the following steps:
1) M.hemolytica KB345 (Tilmicosin-sensitivity strain) and M.hemolytica KB346 (Tilmicosin- low sensitivity strain) were provided. KB 345 strain stored at -80 °C was seeded to BHIB agar medium
(10 mL) by using Microbank beads (Pro-Lab) and platinum nail. After statically incubating the KB 345 strain for 24 hours at 37°C, it was seeded to maintaining slant BHIB agar medium (7 mL) by using platinum loop, further statically incubated for 24 hours at 37°C to obtain slant. One platinum loop of KB 345 strain stored at the slant was inoculated into a large test tube charged with BHIB liquid medium (10 mL) and then incubated for 24 hours at 37 °C with shaking.
2) A paper disc (ADVANTEC, Φ:6 mm) was impregnated with a solution of test compound and dried under reduced pressure.
3) To a melted BHIB agar medium was inoculated 1% of the broth obtained from step 1) above to prepare a test plate. After the medium set, the paper disc prepared in step 2) above was put on the plate and it was incubated at 37°C.
4) After one day, the inhibition zone diameter and clarity (A to E) were determined. For KB346 strain, the same procedures were repeated.
The results of the assays are shown in Tables below:
Table 2. Mannhemia hemolytica KB345:
Inhibition zone (mm) and clarity (A to E)
100
30 mg/ 10 mg/ 3 mg/ 1 mg/ mg/
Sample 20-position substituent 6mm 6mm 6mm 6mm
6mm
disk disk disk disk disk
Tylosin - 11. OA 10.5B - - -
Tilmicosin * NT NT 16.0A 13.5A 10.7A
Tulathromycin - NT NT 18.0A 16.0A 12.5A
YT6 _|.CHO NT 10.5A - - -
Figure imgf000122_0001
Inhibition zone (mm) and clarity (A to E)
100
30 mg/ 10 mg/ 3 mg/ 1 mg/ mg/
Sample 20-position substituent 6mm 6mm 6mm 6mm
6mm
disk disk disk disk disk
YT32 16.0A 14.0A 9.0A - NT
YT33 20.0A 17.0A 16.0A 13.0A NT
YT34 15.0A 14.0A 13.0A 11.0B NT
YT35 21.0A 19.0A 17.0A 14.0A NT
YT36 9.0A - - - NT
N=N
YT37 12.5A 9.0A - - NT
Table 3. Mannhemia hemolytica KB346
Figure imgf000123_0001
Figure imgf000124_0001
Table 4. Mannhemia hemolytica KB345
Figure imgf000125_0002
Table 5. Mannhemia hemolytica KB346
Figure imgf000125_0001
Figure imgf000126_0001
(2) Antibacterial activities against other bacteria were determined with Micrococcus luteus ATCC9341 (1), Bacillus subtilis ATCC663 (s), Escherichia coli NIHJ (c), Xanthomonas campestris KB88 (X), Mucor racemosus IFO 4581 (Mu) and Candida albicans ATCC 64548 (Ca).
Bacillus subtilis ATCC6633 was incubated in Davis synthetic medium and then the seed broth was combined with the medium in the ratio of 1 :99 to obtain a test plate. Micrococcus luteus ATCC9341, Escherichia coli NIHJ and Xanthomonas campestris KB88 were respectively incubated in Nutrient agar medium and inoculated at 0.2%., 0.5% and 1.0%. Mucor racemosus IFO 4581 and Candida albicans ATCC 64548 were respectively incubated in GY agar medium and then inoculated at 0.3%> and 0.2%>.
A paper disc (ADVANTEC, Φ:6 mm) was impregnated with a solution of test compound and dried under reduced pressure. The paper disc was put on the test plate and it was incubated for 24 hours at 37°C. After incubation, the inhibition zone diameter and clarity (A to E) were determined.
The results of the assays are shown in Table 6 below: Table 6. Six bacteria
Figure imgf000127_0001
Minimal inhibitory concentrations (MICs) were determined against the most prevalent pathogens in cattle (Mannheimia Haemolytica, 3 isolates) and swine (A. pleuropneumoniae, 6 isolates). The results are summarized in Table 7.
Table 7. MICs ^g/ml)
Figure imgf000127_0002
(3) Activity against bacterial mastitis pathogens
The activity of several compounds against bacterial mastitis pathogens has been tested under in- vitro conditions according to a recognized procedure (CLSI, document M31 -A3, 2008). In this test 7 to 12 representative bacteria belonging to 7 bacterial species that typically cause mastitis in dairy cattle, i.e. Staphylococcus aureus, coagulase negative staphylococci (CNS), Streptococcus uberis, Streptococus dysgalactiae, Streptococcus agalactiae, Arcanobacterium pyogenes and Escherichia coli, were exposed to two-fold dilutions of the test compounds. After 24 hours of incubation the concentration that inhibited the growth of this bacteria was determined. The results are shown in table 8 below. It could be shown that all these bacterial mastitis pathogens were highly susceptible to the test compounds. Table 8. Minimum inhibitory concentration (broth dilution method) inhibiting 50 % of a population (MIC50, μg/mL) of 7 to 12 isolates belonging to 7 distinct mastitis-causing bacterial species (Staphylococcus aureus, coagulase negative staphylococci [CNS], Streptococcus uberis, Streptococus dysgalactiae, Streptococcus agalactiae, Arcanobacterium pyogenes and Escherichia coli)
Figure imgf000128_0001
In addition the activity of several compounds was tested against two bacterial species, i.e. Mannheimia haemolytica and Actinobacillus pleuropneumoniae, which are considered as the most important bacterial respiratory pathogens in cattle and swine, respectively. As shown in table 9 below these compounds were highly active against these respiratory pathogens.
Table 9. Range of minimum inhibitory concentrations (MIC, μg/mL, broth dilution method) against 3 Mannheimia haemolytica isolates and 6 Actinobacillus pleuropneumoniae isolates
Figure imgf000129_0001
The clinical efficacy of compound YT709 against mastitis caused by S. aureus was shown in lactating mice according to a recognized published procedure (E. Brouillette, G. Grondin, C. Lefebvre, B.G. Talbot, F. Malouin, Mouse mastitis model of infection for antimicrobial compound efficacy studies against intracellular and extracellular forms of Staphylococcus aureus, Veterinary Microbiology, 101, (2004), 253-262). Into the glands of lactating mice S. aureus bacteria (strain Newbould) were instilled and allowed to multiply. Bacterium S. aureus Newbould is an isolate which was isolated from a clinical case of bovine mastitis and which also causes typical mastitis infection in dairy cattle upon experimental, intramammary infection. Four hours after the intramammary infection of lactating mice with S. aureus Newbould, compound YT709 was instilled into the infected glands. Different intramammary dosages of YT709 were tested and their efficacy compared to an infected, untreated control group. Fourteen hours after intramammary application of YT709, the glands of the treated and untreated mice were removed, homogenized and the number of S. aureus bacteria counted in 10-fold dilutions of the homogenized glands. The mean S. aureus count of 8 untreated glands was 108'64 (8.64 loglO) bacteria. The mean S. aureus count in 6 glands that had been treated with 200 microgram YT709 was lO5 10 bacteria (5.10 log 10). Hence in the glands treated with 200 microgram YT709 the number of bacteria was reduced about 3500 fold. The mean S. aureus count in the 5 glands that had been treated with 400 microgram YT709 was lO2 34 bacteria (2.34 loglO). Hence in the glands treated with 400 microgram YT-709 the number of bacteria was reduced about two million fold. In the mice from which the lactating glands had been treated with 400 microgram YT709, S. aureus bacteria could not be counted anymore in measurable numbers and hence in 2 out of 5 glands the infection was cleared.
All references, patent applications and publications cited herein are hereby incorporated by reference in its entirety.

Claims

1. A compound represented by the formula (Ila):
Figure imgf000131_0001
or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof;
wherein, R11 andR12 are each independently selected from
hydrogen;
-CHO;
Ci-Ce-Χ, wherein X is selected from the group consisting of hydroxyl or protected hydroxyl, halogen, and N3;
CN;
Cl -C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic;
C3 -C 14-cyclocyclic;
substituted C3-C14-cycloalkyl;
aryl;
substituted aryl;
heterocyclic;
substituted heterocyclic; or R11 and R12 taken with the nitrogen atom to which they are connected form N3 or a 3- to 7- membered ring which may optionally contain a hetero function selected from the group consisting of - 0-, -NH-, -N(Cl-C6-alkyl)-, -N(aryl) -, -N (heteroaryl)-, -S-, -S(O)- and-S(0)2-;C3-C14 cycloalkyl; and wherein R5 is
hydrogen;
hydroxyl;
protected hydroxyl;
halogen;
-N3; or
N-Y2, wherein each Y is independently selected from the group consisting of hydrogen and Cl- C6-alkyl, or the two Y taken with the nitrogen atom to which they are connected form a 3- to 7- membered ring.
2. The compound of claim 1, wherein:
R5 is hydroxy.
3. The compound of claim 1 or 2, wherein:
at least R11 or R12 is Cl-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic.
4. The compound of claim 3, wherein:
at least R11 or R12 is Cl-C6-alkyl, substituted with one substituent selected from the group consisting of heterocyclic and substituted heterocyclic.
5. The compound of anyone of claims 1 to 4 for use as a medicament.
6. The compound of anyone of claims 1 to 4 for use in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in an animal.
7. Use of the compound of anyone of claims 1 to 4 for the manufacture of a pharmaceutical or veterinary composition for the treatment or prevention of bacterial infections or disorders associated with bacterial infections in an animal.
8. A method for treating or preventing bacterial infections or disorders associated with bacterial infections in an animal, wherein the method comprises administering to the animal a therapeutically effective amount of the compound according to claim 1.
9. A pharmaceutical or veterinary composition comprising a compound according to anyone of claims 1 to 4 and at least one pharmaceutically acceptable carriers.
10. The pharmaceutical or veterinary composition of claim 9 for use in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in an animal.
11. A method for treating or preventing bacterial infections or disorders associated with bacterial infections in an animal, wherein the method comprises administering to the animal a therapeutically effective amount of the composition according to claim 9.
PCT/EP2014/060665 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof WO2014187957A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
NZ714071A NZ714071B2 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
DK14725726.5T DK2999707T3 (en) 2013-05-23 2014-05-23 Tylosin derivatives and process for their preparation.
AU2014270353A AU2014270353B2 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
PL14725726T PL2999707T3 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
KR1020157035927A KR102307218B1 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
CN201480041371.2A CN105408340B (en) 2013-05-23 2014-05-23 Tylosin derivatives and process for their preparation
RU2015155032A RU2714482C2 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for production thereof
US14/891,762 US9771389B2 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
JP2016514434A JP6494600B2 (en) 2013-05-23 2014-05-23 Tyrosin derivative and method for preparing the same
MYPI2015704210A MY184630A (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
CA2913098A CA2913098C (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
BR112015029260A BR112015029260A2 (en) 2013-05-23 2014-05-23 tylosin derivatives and their method of preparation
UAA201512523A UA117751C2 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
NO14725726A NO2999707T3 (en) 2013-05-23 2014-05-23
ES14725726.5T ES2669615T3 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparing them
EP14725726.5A EP2999707B1 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
SI201430717T SI2999707T1 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof
MX2015016118A MX361808B (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof.
IL242543A IL242543B (en) 2013-05-23 2015-11-11 Tylosin derivatives and method for preparation thereof
HK16104565.9A HK1216753A1 (en) 2013-05-23 2016-04-21 Tylosin derivatives and method for preparation thereof
HRP20180877TT HRP20180877T1 (en) 2013-05-23 2018-06-05 Tylosin derivatives and method for preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13169009.1 2013-05-23
EP13169009 2013-05-23

Publications (1)

Publication Number Publication Date
WO2014187957A1 true WO2014187957A1 (en) 2014-11-27

Family

ID=48463869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/060665 WO2014187957A1 (en) 2013-05-23 2014-05-23 Tylosin derivatives and method for preparation thereof

Country Status (26)

Country Link
US (1) US9771389B2 (en)
EP (1) EP2999707B1 (en)
JP (1) JP6494600B2 (en)
KR (1) KR102307218B1 (en)
CN (1) CN105408340B (en)
AU (1) AU2014270353B2 (en)
BR (1) BR112015029260A2 (en)
CA (1) CA2913098C (en)
CL (1) CL2015003433A1 (en)
DK (1) DK2999707T3 (en)
ES (1) ES2669615T3 (en)
HK (1) HK1216753A1 (en)
HR (1) HRP20180877T1 (en)
HU (1) HUE037868T2 (en)
IL (1) IL242543B (en)
MX (1) MX361808B (en)
MY (1) MY184630A (en)
NO (1) NO2999707T3 (en)
PE (1) PE20160207A1 (en)
PL (1) PL2999707T3 (en)
PT (1) PT2999707T (en)
RU (1) RU2714482C2 (en)
SI (1) SI2999707T1 (en)
TR (1) TR201809189T4 (en)
UA (1) UA117751C2 (en)
WO (1) WO2014187957A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758623B2 (en) 2013-12-09 2020-09-01 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2023230702A1 (en) * 2022-06-03 2023-12-07 University Of Manitoba Novel antimicrobial compounds isolated using a machine learning model trained on a high-throughput antibacterial screen

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590885A (en) * 2019-09-30 2019-12-20 郑州大学 20-substituted-5-O-mycaminosyl-tylonolide derivatives
CN112898361A (en) * 2021-02-01 2021-06-04 郑州大学 5-O-mycylamine glycosyl tylosin lactone derivative and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002496A1 (en) * 1992-07-15 1994-02-03 Pfizer Inc. Derivatives of 16-membered ring antibiotic macrolides
US20060014707A1 (en) * 2004-07-13 2006-01-19 Hong Fu Sixteen-member macrolide antiinfective agents
WO2008012343A2 (en) * 2006-07-28 2008-01-31 Intervet International B.V. Macrolide synthesis process
EP2019112A1 (en) * 2007-07-26 2009-01-28 Intervet International BV Macrolide solid-state forms
WO2013076169A1 (en) * 2011-11-25 2013-05-30 Bayer Intellectual Property Gmbh Antibacterial tylosin derivatives and methods for their preparation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443436A (en) * 1982-09-13 1984-04-17 Eli Lilly And Company C-20-Modified macrolide derivatives of the macrolide antibiotics tylosin, desmycosin, macrocin, and lactenocin
IL69666A (en) * 1982-09-13 1987-10-20 Lilly Co Eli 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use
IL71032A0 (en) 1983-02-28 1984-05-31 Lilly Co Eli C-20 and c-23-modified macrolide derivatives
US4468511A (en) * 1983-02-28 1984-08-28 Eli Lilly And Company C-20- And C-23-Modified macrolide derivatives
ZA841277B (en) * 1983-02-28 1985-09-25 Lilly Co Eli C-20-and c-23-modified macrolide derivatives
JPS59186996A (en) * 1983-04-05 1984-10-23 Microbial Chem Res Found 20-deoxy-20-substituted amino-mycaminosylrelonolide
US4921947A (en) 1986-03-31 1990-05-01 Eli Lilly And Company Process for preparing macrolide derivatives
EP0262903A3 (en) * 1986-09-29 1988-11-02 Eli Lilly And Company New acyl derivatives of 20-modified tylosin and desmycosin compounds
ZA939428B (en) 1992-12-21 1995-06-15 Lilly Co Eli Therapeutic for gram-positive diseases of aquatic species
WO1996009312A1 (en) 1994-09-22 1996-03-28 Pfizer Inc. Antibiotic macrolides
AU763732B2 (en) * 1999-08-30 2003-07-31 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Macrolide antibiotics and treatment of pasteurellosis
US6506885B1 (en) * 2001-09-27 2003-01-14 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to the drug tilmicosin and a method for detecting the same
US6576615B2 (en) 2001-11-08 2003-06-10 Enanta Pharmaceuticals, Inc. 4′-O-substituted tylosin analogs
US6664240B2 (en) * 2001-11-15 2003-12-16 Enanta Pharmaceuticals, Inc. Tylosin derivatives having antibacterial activity
US6710034B2 (en) 2002-04-19 2004-03-23 Enanta Pharmaceuticals, Inc. 5-O-mycaminosyltylonide derivatives
US6753415B2 (en) 2002-04-19 2004-06-22 Enanta Pharmaceuticals, Inc. 23-O-substituted 5-O-mycaminosyltylonide derivatives
WO2005118610A2 (en) 2004-06-01 2005-12-15 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
DE102005061326A1 (en) 2005-12-20 2007-06-21 Basell Polyolefine Gmbh Preparation of metallocene compound, useful e.g. in the preparation of isotactic polypropylene, comprises using a cyclopentadienyl derivative that is recycled from the filtrate obtained from the preparation of e.g. metallocene compound
UA98303C2 (en) * 2006-07-28 2012-05-10 Интервет Интернешонал Б.В. Macrolide synthesis process
WO2009064953A1 (en) 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
US20110071096A1 (en) * 2009-09-23 2011-03-24 Idexx Laboratories, Inc. Macrolides Having Antibiotic Activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002496A1 (en) * 1992-07-15 1994-02-03 Pfizer Inc. Derivatives of 16-membered ring antibiotic macrolides
US20060014707A1 (en) * 2004-07-13 2006-01-19 Hong Fu Sixteen-member macrolide antiinfective agents
WO2008012343A2 (en) * 2006-07-28 2008-01-31 Intervet International B.V. Macrolide synthesis process
EP2019112A1 (en) * 2007-07-26 2009-01-28 Intervet International BV Macrolide solid-state forms
WO2013076169A1 (en) * 2011-11-25 2013-05-30 Bayer Intellectual Property Gmbh Antibacterial tylosin derivatives and methods for their preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FU H ET AL: "Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 5, 1 March 2006 (2006-03-01), pages 1259 - 1266, XP027965702, ISSN: 0960-894X, [retrieved on 20060301] *
HERBERT A. KIRST ET AL: "Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics", JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 8, 1 August 1988 (1988-08-01), pages 1631 - 1641, XP055131258, ISSN: 0022-2623, DOI: 10.1021/jm00403a025 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758623B2 (en) 2013-12-09 2020-09-01 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US11529420B2 (en) 2013-12-09 2022-12-20 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2023230702A1 (en) * 2022-06-03 2023-12-07 University Of Manitoba Novel antimicrobial compounds isolated using a machine learning model trained on a high-throughput antibacterial screen

Also Published As

Publication number Publication date
US20160108077A1 (en) 2016-04-21
HK1216753A1 (en) 2016-12-02
MX361808B (en) 2018-12-14
PT2999707T (en) 2018-05-23
RU2015155032A (en) 2017-06-27
CA2913098A1 (en) 2014-11-27
HUE037868T2 (en) 2018-09-28
RU2714482C2 (en) 2020-02-18
AU2014270353A1 (en) 2015-11-26
IL242543B (en) 2020-10-29
MX2015016118A (en) 2016-06-21
TR201809189T4 (en) 2018-07-23
NO2999707T3 (en) 2018-08-25
EP2999707B1 (en) 2018-03-28
BR112015029260A2 (en) 2017-07-25
CN105408340B (en) 2020-06-12
SI2999707T1 (en) 2018-07-31
JP6494600B2 (en) 2019-04-03
HRP20180877T1 (en) 2018-07-13
JP2016519153A (en) 2016-06-30
PL2999707T3 (en) 2018-09-28
UA117751C2 (en) 2018-09-25
CA2913098C (en) 2021-11-02
AU2014270353B2 (en) 2018-09-20
CL2015003433A1 (en) 2016-07-15
EP2999707A1 (en) 2016-03-30
DK2999707T3 (en) 2018-06-06
KR102307218B1 (en) 2021-10-05
US9771389B2 (en) 2017-09-26
NZ714071A (en) 2020-12-18
RU2015155032A3 (en) 2018-04-28
ES2669615T3 (en) 2018-05-28
PE20160207A1 (en) 2016-05-22
KR20160014656A (en) 2016-02-11
CN105408340A (en) 2016-03-16
MY184630A (en) 2021-04-11

Similar Documents

Publication Publication Date Title
AU2012342548B2 (en) Antibacterial tylosin derivatives and methods for their preparation
US20080262208A1 (en) 6-11 Bridged Oxime Erythromycin Derivatives
AU2014270353B2 (en) Tylosin derivatives and method for preparation thereof
US7291602B2 (en) 11,12-lactone bicyclolides
US20060252710A1 (en) 6-11 Bridged oxime erythromycin derivatives
BG107168A (en) The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
US7312201B2 (en) Tetracyclic bicyclolides
EP1262186A1 (en) Azalide antibiotic compositions
NZ714071B2 (en) Tylosin derivatives and method for preparation thereof
US20080027012A1 (en) Bridged carbamate macrolides
US7407942B2 (en) 3,6-bridged 9,12-oxolides
NZ625402B2 (en) Antibacterial tylosin derivatives and methods for their preparation
MXPA01001212A (en) 13 and 14-membered antibacterial macrolides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480041371.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14725726

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 242543

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 14891762

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016514434

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2913098

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/016118

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15278262

Country of ref document: CO

Ref document number: 002434-2015

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 2014725726

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014270353

Country of ref document: AU

Date of ref document: 20140523

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015029260

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157035927

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015155032

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201512523

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 112015029260

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151123